Oligonucleotides for DGAT2 modulation

JP2023550485A5Pending Publication Date: 2024-11-29UNIV OF MASSACHUSETTS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530843
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-23
Filing Date
2021-11-22
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are severe complications of type 2 diabetes, often associated with obesity and lipodystrophy, primarily caused by the accumulation of triglycerides in the liver due to the enzyme diacylglycerol O-acyltransferase 2 (DGAT2), which catalyzes the final step in triglyceride synthesis.

Method used

Development of double-stranded RNA (dsRNA) molecules targeting the DGAT2 gene, comprising specific antisense strands complementary to DGAT2 nucleic acid sequences, to inhibit DGAT2 expression and reduce triglyceride accumulation in the liver.

Benefits of technology

The dsRNA molecules effectively inhibit DGAT2 gene expression, leading to a significant reduction in liver triglycerides, thereby treating or preventing NAFLD and NASH, as well as associated conditions like lipodystrophy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022109398000001
    Figure 2022109398000001
  • Figure 2022109398000002
    Figure 2022109398000002
  • Figure 2022109398000003
    Figure 2022109398000003
Patent Text Reader

Abstract

The present disclosure relates to novel DGAT2 targeting sequences. Novel DGAT2 targeting oligonucleotides for the treatment of non-alcoholic fatty liver disease (NAFLD) and lipodystrophy syndrome (or metabolic syndrome) are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Related Applications This application claims the benefit of U.S. Provisional Patent Application No. 63 / 117,005, filed November 23, 2020, the entire disclosure of which is incorporated herein by reference in its entirety.

[0002] Description of Research Funded by Federal Government This invention was made with government support under Grant No. DK103047 awarded by the National Institutes of Health. The government has certain rights in this invention.

[0003] Technical Field The present disclosure relates to DGAT2-targeting sequences and methods for treating and preventing non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and lipodystrophy syndrome.

Background Art

[0004] One of the many serious complications of type 2 diabetes is the accumulation of triglycerides in the liver (referred to as non-alcoholic fatty liver disease, NAFLD), which can eventually lead to severe liver inflammation and fibrosis (referred to as non-alcoholic steatohepatitis, NASH). Since genetic mutations that cause NAFLD in humans also contribute to the development of NASH, at least part of the characteristics of NASH seems to be caused by fat accumulation. The fact that NASH is rapidly becoming a major cause of liver transplantation highlights the severity of NASH. The onset of NAFLD is associated with obesity and lipodystrophy in humans, and both NAFLD and NASH are often the most severe in type 2 diabetes, and currently 10% of the U.S. population suffers from type 2 diabetes.

[0005] There are multiple mechanisms in the liver that lead to NAFLD, and these mechanisms may include fatty acids entering the liver from adipose tissue, from circulating lipoproteins, or from the synthesis of fatty acids (referred to as de novo lipogenesis) from carbohydrates and other substrates in the liver. Fatty acids in the liver are esterified to triglycerides via a synthetic pathway that combines fatty acids with glycerol (triglycerides accumulate and cause NAFLD). The final step in this triglyceride synthesis pathway in the liver is mainly catalyzed by the enzyme diacylglycerol O-acyltransferase 2 (DGAT2), which binds a third fatty acid onto diacylglycerol to produce triglycerides. Inhibition of DGAT2 may be a useful therapeutic approach for the treatment of liver diseases such as NAFLD and NASH.

Summary of the Invention

[0006] In one aspect, the present disclosure provides a double-stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, wherein the antisense strand comprises a sequence substantially complementary to the diacylglycerol O-acyltransferase 2 (DGAT2) nucleic acid sequence of any one of SEQ ID NOs: 1-5.

[0007] In one aspect, the present disclosure provides a double-stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, wherein the antisense strand comprises a sequence substantially complementary to the diacylglycerol O-acyltransferase 2 (DGAT2) nucleic acid sequence of SEQ ID NO: 1.

[0008] In one aspect, the present disclosure provides a double-stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, wherein the antisense strand comprises a sequence substantially complementary to the diacylglycerol O-acyltransferase 2 (DGAT2) nucleic acid sequence of SEQ ID NO: 2.

[0009] In one embodiment, the present disclosure provides a double-stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, wherein the antisense strand comprises a sequence substantially complementary to the diacylglycerol O-acyltransferase 2 (DGAT2) nucleic acid sequence of Sequence ID No. 3.

[0010] In one embodiment, the present disclosure provides a double-stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, wherein the antisense strand comprises a sequence substantially complementary to the diacylglycerol O-acyltransferase 2 (DGAT2) nucleic acid sequence of Sequence ID No. 4.

[0011] In one embodiment, the present disclosure provides a double-stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, wherein the antisense strand comprises a sequence substantially complementary to the diacylglycerol O-acyltransferase 2 (DGAT2) nucleic acid sequence of Sequence ID No. 5.

[0012] In certain embodiments, the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs. 6 to 10.

[0013] In certain embodiments, the dsRNA includes complementarity to at least 10, 11, 12, or 13 consecutive nucleotides of any one of the DGAT2 nucleic acid sequences of SEQ ID NOs. In certain embodiments, the dsRNA includes three or fewer mismatches with any one of the DGAT2 nucleic acid sequences of SEQ ID NOs. In certain embodiments, the dsRNA includes complete complementarity to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs.

[0014] In certain embodiments, the antisense chain is approximately 15 to 25 nucleotides long. In certain embodiments, the sense chain is approximately 15 to 25 nucleotides long. In certain embodiments, the antisense chain is 20 nucleotides long. In certain embodiments, the antisense chain is 21 nucleotides long. In certain embodiments, the antisense chain is 22 nucleotides long. In certain embodiments, the sense chain is 15 nucleotides long. In certain embodiments, the sense chain is 16 nucleotides long. In certain embodiments, the sense chain is 18 nucleotides long. In certain embodiments, the sense chain is 20 nucleotides long. In certain embodiments, the sense chain is 21 nucleotides long.

[0015] In certain embodiments, the dsRNA includes a double-stranded region of 15 to 20 base pairs. In certain embodiments, the dsRNA includes a double-stranded region of 15 base pairs. In certain embodiments, the dsRNA includes a double-stranded region of 16 base pairs. In certain embodiments, the dsRNA includes a double-stranded region of 18 base pairs. In certain embodiments, the dsRNA includes a double-stranded region of 20 base pairs. In certain embodiments, the dsRNA includes a double-stranded region of 21 base pairs.

[0016] In certain embodiments, the dsRNA includes a blunt end. In certain embodiments, the dsRNA includes at least one single-stranded nucleotide overhang. In certain embodiments, the dsRNA includes a single-stranded nucleotide overhang of approximately 2 to 5 nucleotides. In certain embodiments, the dsRNA includes a single-stranded nucleotide overhang of 2 nucleotides. In certain embodiments, the dsRNA includes a single-stranded nucleotide overhang of 5 nucleotides.

[0017] In certain embodiments, the dsRNA includes naturally occurring nucleotides.

[0018] In certain embodiments, the dsRNA comprises at least one modified nucleotide.

[0019] In certain embodiments, the modified nucleotides include 2'-O-methyl modified nucleotides, 2'-deoxy-2'-fluoro modified nucleotides, 2'-deoxy modified nucleotides, locked nucleotides, debased nucleotides, 2'-amino modified nucleotides, 2'-alkyl modified nucleotides, morpholino nucleotides, phosphoramides, non-natural bases including nucleotides, or mixtures thereof.

[0020] In certain embodiments, the dsRNA includes at least one modified nucleotide linkage.

[0021] In certain embodiments, the modified nucleotide linkages include phosphorothioate nucleotide linkages. In certain embodiments, the dsRNA includes 4 to 16 phosphorothioate nucleotide linkages. In certain embodiments, the dsRNA includes 8 or 13 phosphorothioate nucleotide linkages. In certain embodiments, the dsRNA includes 4 or 9 phosphorothioate nucleotide linkages. In certain embodiments, the sense strand includes 4 phosphorothioate nucleotide linkages.

[0022] In a particular embodiment, the above dsRNA is of formula I: [ka] (In the formula, B is the base pair portion; W is selected from the group consisting of O, OCH2, OCH, CH2, and CH; X is a halo, hydroxy, and C 1-6 Selected from the group consisting of alkoxys, Y is O - OH, OR, NH - NH2, S - Selected from the group consisting of , and SH, Z is selected from the group consisting of O and CH2; R is a protecting group; [ka] (This is a bond that is a double bond by choice.) It includes at least one modified nucleotide linkage.

[0023] In certain embodiments, the dsRNA contains at least 80% chemically modified nucleotides. In certain embodiments, the dsRNA is fully chemically modified. In certain embodiments, the dsRNA contains at least 70% 2'-O-methyl nucleotide modifications. In certain embodiments, the antisense strand contains at least 70% 2'-O-methyl nucleotide modifications. In certain embodiments, the antisense strand contains 70% to 90% 2'-O-methyl nucleotide modifications. In certain embodiments, the sense strand contains at least 65% 2'-O-methyl nucleotide modifications. In certain embodiments, the sense strand contains 100% 2'-O-methyl nucleotide modifications.

[0024] In certain embodiments, the sense strand contains one or more nucleotide mismatches between the antisense strand and the sense strand. In certain embodiments, the one or more nucleotide mismatches are located at positions 2, 6, and 12 from the 5' end of the sense strand. In certain embodiments, the nucleotide mismatches are located at positions 2, 6, and 12 from the 5' end of the sense strand.

[0025] In certain embodiments, the antisense chain comprises a 5'-phosphate, a 5'-alkylphosphonate, a 5'-alkylenephosphonate, or a 5'-alkenylphosphonate. In certain embodiments, the antisense chain comprises a 5'-vinylphosphonate.

[0026] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, wherein (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand comprises at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, 14, and 16 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1 to 2 to 1 to 7 from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand comprises at least 70% 2'-O-methyl modifications; and (7) the nucleotides at positions 1 to 2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0027] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, wherein (1) the antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 4, 5, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1-2 to 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains 100% 2'-O-methyl modifications; and (7) the nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0028] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, wherein (1) the antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 4, 5, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1-2 to 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains 100% 2'-O-methyl modifications; and (7) the nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0029] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, wherein (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand comprises at least 80% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 4, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1-2 to 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand comprises at least 80% 2'-O-methyl modifications; and (7) the nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0030] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, and (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand comprises at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, 14, 16, and 20 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1 to 2 from the 3' end of the antisense strand (5) The nucleotides from position 1 to 7 are linked to each other via phosphorothioate nucleotide linkages; (6) A portion of the antisense strand is complementary to a portion of the sense strand; (7) The sense strand contains at least 70% 2'-O-methyl modification; (8) The nucleotides from the 3' end of the sense strand to positions 7 and 9 to 11 are not 2'-methoxyribonucleotides; (9) The nucleotides from the 5' end of the sense strand to positions 1 to 2 are linked to each other via phosphorothioate nucleotide linkages.

[0031] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, and (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand comprises at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1 to 2 from the 3' end of the antisense strand are (5) The nucleotides at positions ~7 are linked to each other via phosphorothioate nucleotide linkages; (6) A portion of the antisense strand is complementary to a portion of the sense strand; (7) The sense strand contains at least 70% 2'-O-methyl modification; (8) The nucleotides at positions 7, 10, and 11 from the 3' end of the sense strand are not 2'-methoxy-ribonucleotides; (9) The nucleotides at positions 1~2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0032] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, and (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand comprises at least 50% 2'-O-methyl modification; (3) the nucleotides at positions 2, 4, 6, 8, 10, 12, 14, and 16 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1 to 2 from the 3' end of the antisense strand (5) The nucleotides from position 1 to 7 are linked to each other via phosphorothioate nucleotide linkages; (6) A portion of the antisense strand is complementary to a portion of the sense strand; (7) The sense strand contains at least 65% 2'-O-methyl modification; (8) The nucleotides from position 3, 7, 9, 11, and 13 of the sense strand from the 3' end are not 2'-methoxy-ribonucleotides; (9) The nucleotides from position 1 to 2 of the sense strand from the 5' end are linked to each other via phosphorothioate nucleotide linkages.

[0033] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, wherein (1) the antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 85% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 14, and 20 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1-2 to 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains 100% 2'-O-methyl modifications; and (7) the nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0034] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, and (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand comprises at least 75% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, 14, 16, and 20 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1 to 2 from the 3' end of the antisense strand are (1) The nucleotides at positions 1-7 are linked to each other via phosphorothioate nucleotide linkages; (5) A portion of the antisense strand is complementary to a portion of the sense strand; (6) The sense strand contains at least 75% 2'-O-methyl modification; (7) The nucleotides at positions 7, 9, 10, and 11 from the 3' end of the sense strand are not 2'-methoxy-ribonucleotides; (8) The nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0035] In certain embodiments, the nucleotides from the 5' end to the 20th position of the antisense strand are not 2'-methoxyribonucleotides.

[0036] In certain embodiments, the functional portion is connected to the 5' end and / or 3' end of the antisense chain. In certain embodiments, the functional portion is connected to the 5' end and / or 3' end of the sense chain. In certain embodiments, the functional portion is connected to the 3' end of the sense chain. In certain embodiments, the functional portion is connected to the 3' end of the sense chain.

[0037] In certain embodiments, the functional portion includes an N-acetylgalactosamine (GalNAc) moiety.

[0038] In certain embodiments, the functional portion includes a hydrophobic portion.

[0039] In certain embodiments, the hydrophobic moiety is selected from the group consisting of fatty acids, steroids, secosteroids, lipids, gangliosides, nucleoside analogs, endocannabinoids, vitamins, and mixtures thereof.

[0040] In certain embodiments, the steroid is selected from the group consisting of cholesterol and lithocholic acid (LCA).

[0041] In certain embodiments, the fatty acid is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosanic acid (DCA).

[0042] In certain embodiments, the functional portion is linked to the antisense and / or sense chain by a linker. In certain embodiments, the linker includes a divalent or trivalent linker.

[0043] In certain embodiments, the linker is a cleavable linker. In certain embodiments, the cleavable linker includes a phosphodiester bond, a disulfide bond, an acid-unstable bond, or a photocleavable bond.

[0044] In certain embodiments, the cleavable linker comprises a dTdT dinucleotide having inter-phosphodiester nucleotide links.

[0045] In certain embodiments, the acid-unstable bond includes a β-thiopropionate bond or a carboxydimethylmaleic anhydride (CDM) bond.

[0046] In certain embodiments, the divalent or trivalent linker is [ka] (In the formula, n is 1, 2, 3, 4, or 5) Selected from.

[0047] In certain embodiments, the linker includes an ethylene glycol chain, an alkyl chain, a peptide, RNA, DNA, a phosphodiester, a phosphorothioate, a phosphoramidate, an amide, a carbamate, or a combination thereof.

[0048] In certain embodiments, if the linker is a trivalent linker, the linker further links a phosphodiester or a phosphodiester derivative.

[0049] In certain embodiments, the phosphodiester or phosphodiester derivative is [ka] (In the formula, X is O, S, or BH3) It is selected from the group consisting of the following.

[0050] In certain embodiments, the nucleotides at positions 1 and 2 from the 3' end of the sense strand, and the nucleotides at positions 1 and 2 from the 5' end of the antisense strand, are linked to adjacent ribonucleotides via phosphorothioate bonds.

[0051] In certain embodiments, the dsRNA inhibits the expression of the DGAT2 gene by at least about 50%.

[0052] In certain embodiments, the dsRNA inhibits the expression of one or more of the SREBP1c, FASN, SCD1, and ACC1 genes by at least about 50%.

[0053] In another embodiment, the disclosure provides a pharmaceutical composition for inhibiting the expression of the diacylglycerol O-acyltransferase 2 (DGAT2) gene in an organism, comprising the dsRNA and a pharmaceutically acceptable carrier.

[0054] In certain embodiments, the dsRNA inhibits the expression of the DGAT2 gene by at least about 50%. In certain embodiments, the dsRNA inhibits the expression of the DGAT2 gene by at least about 80%.

[0055] In another aspect, the present disclosure provides a method for inhibiting the expression of the DGAT2 gene in cells, comprising: (a) introducing the double-stranded ribonucleic acid (dsRNA) into the cells; and (b) maintaining the cells produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the DGAT2 gene, thereby inhibiting the expression of the DGAT2 gene in the cells.

[0056] In another embodiment, the present disclosure provides a method for treating or managing a disease related to DGAT2, comprising administering a therapeutically effective amount of the dsRNA to a patient in need of such treatment.

[0057] In certain embodiments, the disease is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), lipodystrophy, partial lipodystrophy, metabolic syndrome, cardiovascular disease, or a combination thereof.

[0058] In certain embodiments, the dsRNA is administered to either or both the liver and / or white adipose tissue of the patient.

[0059] In certain embodiments, the dsRNA is administered by intravenous (IV) injection, subcutaneous (SQ) injection, or a combination thereof.

[0060] In certain embodiments, administration of the above dsRNA causes a decrease in DGAT2 gene mRNA in one or more of the liver and white adipose tissue. In certain embodiments, administration of the above dsRNA causes a decrease in DGAT2 gene mRNA in one or more of the hepatocytes and adipocytes.

[0061] In certain embodiments, the dsRNA inhibits the expression of the DGAT2 gene by at least about 50%. In certain embodiments, the dsRNA inhibits the expression of the DGAT2 gene by at least about 80%.

[0062] In certain embodiments, DGAT2 gene expression is inhibited by at least approximately 50% for 4 weeks after administration. In certain embodiments, DGAT2 gene expression is inhibited by at least approximately 50% for 8 weeks after administration. In certain embodiments, DGAT2 gene expression is inhibited by at least approximately 50% for 12 weeks after administration.

[0063] In certain embodiments, the dsRNA is administered at doses of approximately 1 mg / kg, approximately 3 mg / kg, or approximately 10 mg / kg.

[0064] In one embodiment, the disclosure provides a vector comprising a regulatory sequence operably ligated to a nucleotide sequence encoding a dsRNA molecule substantially complementary to the DGAT2 nucleic acid sequences of SEQ ID NOs. 1-10.

[0065] In certain embodiments, the dsRNA molecule inhibits the expression of the DGAT2 gene by at least 30%. In certain embodiments, the dsRNA molecule inhibits the expression of the DGAT2 gene by at least about 50%. In certain embodiments, the dsRNA molecule inhibits the expression of the DGAT2 gene by at least about 80%.

[0066] In certain embodiments, the dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a sequence substantially complementary to the DGAT2 nucleic acid sequences of SEQ ID NOs. 1 to 10.

[0067] In one embodiment, the present disclosure provides cells containing the above-mentioned vector.

[0068] In one embodiment, the disclosure provides a recombinant adeno-associated virus (rAAV) comprising the above-mentioned vector and AAV capsid.

[0069] In one embodiment, the present disclosure provides a method for treating or managing a disease related to DGAT2, comprising administering to a patient in need of such treatment a double-stranded RNA (dsRNA) molecule comprising a therapeutically effective dose of a sense strand and an antisense strand, wherein the antisense strand comprises a sequence substantially complementary to the diacylglycerol O-acyltransferase 2 (DGAT2) nucleic acid sequence, and the dsRNA molecule inhibits DGAT2 gene expression by at least about 50% for four weeks after administration.

[0070] In certain embodiments, the dsRNA molecule inhibits DGAT2 gene expression by at least approximately 50% for 8 weeks after administration. In certain embodiments, the dsRNA molecule inhibits DGAT2 gene expression by at least approximately 50% for 12 weeks after administration.

[0071] In certain embodiments, the dsRNA molecule inhibits DGAT2 gene expression by approximately 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%.

[0072] In certain embodiments, the dsRNA molecule is administered at a dose of approximately 0.1 mg / kg to approximately 100 mg / kg.

[0073] In certain embodiments, the dsRNA molecule is administered in doses of approximately 0.1 mg / kg, approximately 0.3 mg / kg, approximately 0.5 mg / kg, approximately 1 mg / kg, approximately 3 mg / kg, approximately 5 mg / kg, approximately 10 mg / kg, approximately 15 mg / kg, approximately 20 mg / kg, approximately 25 mg / kg, or approximately 30 mg / kg.

[0074] In certain embodiments, the antisense strand comprises a sequence substantially complementary to the DGAT2 nucleic acid sequences of SEQ ID NOs. 1 to 10.

[0075] In certain embodiments, the antisense strand includes complementarity to at least 10, 11, 12, or 13 consecutive nucleotides of any one of the DGAT2 nucleic acid sequences of SEQ ID NOs. In certain embodiments, the antisense strand includes three or fewer mismatches with any one of the DGAT2 nucleic acid sequences of SEQ ID NOs. In certain embodiments, the antisense strand includes complete complementarity to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs.

[0076] In certain embodiments, the antisense chain is approximately 15 to 25 nucleotides long. In certain embodiments, the sense chain is approximately 15 to 25 nucleotides long. In certain embodiments, the antisense chain is 20 nucleotides long. In certain embodiments, the antisense chain is 21 nucleotides long. In certain embodiments, the antisense chain is 22 nucleotides long. In certain embodiments, the sense chain is 15 nucleotides long. In certain embodiments, the sense chain is 16 nucleotides long. In certain embodiments, the sense chain is 18 nucleotides long. In certain embodiments, the sense chain is 20 nucleotides long.

[0077] In certain embodiments, the dsRNA molecule includes a double-stranded region of 15 to 20 base pairs. In certain embodiments, the dsRNA molecule includes a double-stranded region of 15 base pairs. In certain embodiments, the dsRNA molecule includes a double-stranded region of 16 base pairs. In certain embodiments, the dsRNA molecule includes a double-stranded region of 18 base pairs. In certain embodiments, the dsRNA molecule includes a double-stranded region of 20 base pairs.

[0078] In certain embodiments, the dsRNA includes a blunt end.

[0079] In certain embodiments, the dsRNA contains at least one single-stranded nucleotide overhang. In certain embodiments, the dsRNA contains a single-stranded nucleotide overhang of approximately 2 to 5 nucleotides. In certain embodiments, the dsRNA contains a single-stranded nucleotide overhang of 2 nucleotides. In certain embodiments, the dsRNA contains a single-stranded nucleotide overhang of 5 nucleotides.

[0080] In certain embodiments, the dsRNA comprises at least one modified nucleotide.

[0081] In certain embodiments, the modified nucleotides include 2'-O-methyl modified nucleotides, 2'-deoxy-2'-fluoro modified nucleotides, 2'-deoxy modified nucleotides, locked nucleotides, debased nucleotides, 2'-amino modified nucleotides, 2'-alkyl modified nucleotides, morpholino nucleotides, phosphoramides, non-natural bases including nucleotides, or mixtures thereof.

[0082] In certain embodiments, the dsRNA includes at least one modified nucleotide linkage.

[0083] In certain embodiments, the modified nucleotide linkages include phosphorothioate nucleotide linkages. In certain embodiments, the dsRNA includes 4 to 16 phosphorothioate nucleotide linkages. In certain embodiments, the dsRNA includes 4 to 13 phosphorothioate nucleotide linkages. In certain embodiments, the dsRNA includes 8 or 13 phosphorothioate nucleotide linkages. In certain embodiments, the antisense strand includes 4 or 9 phosphorothioate nucleotide linkages. In certain embodiments, the sense strand includes 4 phosphorothioate nucleotide linkages.

[0084] In certain embodiments, the dsRNA contains at least 80% chemically modified nucleotides. In certain embodiments, the dsRNA is fully chemically modified. In certain embodiments, the dsRNA contains at least 70% 2'-O-methyl nucleotide modifications. In certain embodiments, the antisense strand contains at least 70% 2'-O-methyl nucleotide modifications. In certain embodiments, the antisense strand contains 70% to 90% 2'-O-methyl nucleotide modifications. In certain embodiments, the sense strand contains at least 65% 2'-O-methyl nucleotide modifications. In certain embodiments, the sense strand contains 100% 2'-O-methyl nucleotide modifications.

[0085] In certain embodiments, the antisense chain comprises a 5'-phosphate, a 5'-alkylphosphonate, a 5'-alkylenephosphonate, or a 5'-alkenylphosphonate. In certain embodiments, the antisense chain comprises a 5'-vinylphosphonate.

[0086] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, wherein (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand comprises at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, 14, and 16 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1 to 2 to 1 to 7 from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand comprises at least 70% 2'-O-methyl modifications; and (7) the nucleotides at positions 1 to 2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0087] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, wherein (1) the antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 4, 5, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1-2 to 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains 100% 2'-O-methyl modifications; and (7) the nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0088] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, wherein (1) the antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 4, 5, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1-2 to 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains 100% 2'-O-methyl modifications; and (7) the nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0089] In a particular embodiment, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end. (1) The antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) The antisense strand contains at least 80% 2'-O-methyl modifications; (3) The nucleotides at positions 2, 4, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) The nucleotides at positions 1-2 to 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) Part of the antisense strand is complementary to part of the sense strand; (6) The sense strand contains at least 80% 2'-O-methyl modifications; (7) The nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0090] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, and (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand comprises at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, 14, 16, and 20 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1 to 2 from the 3' end of the antisense strand (5) The nucleotides from position 1 to 7 are linked to each other via phosphorothioate nucleotide linkages; (6) A portion of the antisense strand is complementary to a portion of the sense strand; (7) The sense strand contains at least 70% 2'-O-methyl modification; (8) The nucleotides from the 3' end of the sense strand to positions 7 and 9 to 11 are not 2'-methoxyribonucleotides; (9) The nucleotides from the 5' end of the sense strand to positions 1 to 2 are linked to each other via phosphorothioate nucleotide linkages.

[0091] In certain embodiments, the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end, and (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand comprises at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1 to 2 from the 3' end of the antisense strand are (5) The nucleotides at positions ~7 are linked to each other via phosphorothioate nucleotide linkages; (6) A portion of the antisense strand is complementary to a portion of the sense strand; (7) The sense strand contains at least 70% 2'-O-methyl modification; (8) The nucleotides at positions 7, 10, and 11 from the 3' end of the sense strand are not 2'-methoxy-ribonucleotides; (9) The nucleotides at positions 1~2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0092] In certain embodiments, the nucleotides from the 5' end to the 20th position of the antisense strand are not 2'-methoxyribonucleotides.

[0093] In certain embodiments, the functional portion is connected to the 5' and / or 3' ends of the antisense chain. In certain embodiments, the functional portion is connected to the 5' and / or 3' ends of the sense chain. In certain embodiments, the functional portion is connected to the 3' end of the sense chain.

[0094] In certain embodiments, the functional portion includes an N-acetylgalactosamine (GalNAc) moiety.

[0095] In certain embodiments, the functional portion includes a hydrophobic portion.

[0096] In certain embodiments, the hydrophobic moiety is selected from the group consisting of fatty acids, steroids, secosteroids, lipids, gangliosides, nucleoside analogs, endocannabinoids, vitamins, and mixtures thereof.

[0097] In certain embodiments, the steroid is selected from the group consisting of cholesterol and lithocholic acid (LCA).

[0098] In certain embodiments, the fatty acid is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosanic acid (DCA).

[0099] The above and other features and advantages of this disclosure will be better understood from the detailed description of the exemplary embodiments in conjunction with the accompanying drawings. This patent or application document includes at least one drawing drawn in color. Copies of this patent or patent application publication including the color drawing(s) are available from the Patent Office upon request and payment of the necessary fees. [Brief explanation of the drawing]

[0100] [Figure 1A] This is a schematic diagram showing the cholesterol conjugate siRNA used in the in vitro screening of cholesterol conjugate siRNA sequences targeting the diacylglycerol O-acyltransferase 2 (DGAT2) gene, as part of a series of diagrams illustrating this in vitro screening. [Figure 1B] Figure 1A is a schematic diagram showing the target site of the screening siRNA on the mouse DGAT2 transcript for silencing, as shown in a series of diagrams. [Figure 1C] Figure 1A shows a series of graphs in which seven screening siRNAs at a concentration of 1.5 μM were tested in the FL83b mouse hepatocyte line, and DGAT2 1093, 1473, and DGAT2 1476 were identified as effective target regions. [Figure 1D]Figure 1A shows a series of graphs illustrating that, based on screening results for three target sites identified in HepG2 cells, targeting the 1473 and 1476 regions of the human DGAT2 transcript with siRNA silencing strongly reduces human DGAT2 mRNA expression. The knockdown rates normalized to HPRT expression are shown. [Figure 1E] Figure 1A shows a series of graphs illustrating dose-response curves in HepG2 cells using eight serial dilution doses of two lead chemically modified siRNAs (1473 and 1476), with IC50 values ​​indicating strong efficacy. [Figure 2A] This study demonstrates in vivo DGAT2 silencing in mice using cholesterol-conjugate chemically modified siRNA that does not contain vinyl phosphonate (VP) modification of the 5' antisense strand. In this experiment, 8-week-old wild-type C57BL6 / J mice fed solid diet were subcutaneously injected with 10 mg / kg of cholesterol-conjugate untargeted control siRNA (NTC), DGAT2-targeted cholesterol-conjugate compound 1473 (Chol-1473), or DGAT2-targeted cholesterol-conjugate compound 1476 (Chol-1476). Mice were sacrificed 10 days after injection. Liver samples were processed for measurement of DGAT2 mRNA expression. [Figure 2B] Following the procedure described in Figure 2A, liver samples were processed for measurement of DGAT2 protein knockdown levels. [Figure 3A] This is a schematic diagram of the GalNAc conjugate siRNA used in the experiment, as part of a series of figures demonstrating in vivo DGAT2 silencing in mice by the N-acetylgalactosamine (GalNAc) conjugate 1473 tool compound (P5 configuration with VP modification). [Figure 3B]Figure 3A shows a series of graphs illustrating the dose-response and KD lifespan of GalNAc-1473. Mice were administered a single subcutaneous injection of either the indicated doses (10, 3, or 1 mg / kg) or a non-targeted control compound (10 mg / kg), and were sacrificed at the indicated time points after injection (4, 8, and 12 weeks). Hepatic DGAT2 silencing was still sufficient 12 weeks after a single subcutaneous injection of GalNAc-1473. [Figure 3C] Figure 3A is a graph showing the changes in de novo lipid biosynthesis-related gene expression in wild-type mice when DGAT2 is knocked down. [Figure 4A] This figure shows the protocol for creating a human hepatocyte transplantation NSG mouse model. [Figure 4B] This graph shows the levels of mouse DGAT2 transcripts one week after injection of GalNac-1473 into mice, demonstrating significant silencing of siRNA homologous to the above transcript. [Figure 4C] This graph shows the levels of human DGAT2 transcript one week after GalNac-1473 injection in mice, demonstrating significant silencing of siRNA homologous to the above transcript. [Figure 5A] Among a series of figures showing the reduction in liver weight and lipid droplet / fat accumulation in an in vivo efficacy study of DGAT2 knockdown and high-fat diet in genetically obese mice (here, 10-week-old genetically obese mice were subcutaneously injected with a 10 mg / kg dose of GalNAc-NTC or GalNAc-1473 and switched to a high-fat, high-cholesterol Gubra Amylin NASH (GAN) diet for 3 weeks. Blood was collected from the animals weekly, and they were sacrificed after 3 weeks, after which the above injections, liver, and plasma were used for analysis), this is a graph showing DGAT2 transcript levels and protein levels in the liver after GalNAc-1473 injection. [Figure 5B] This graph shows a comparison of body weight (start vs. 3 weeks after feeding with GAN diet) following the experimental procedure described in Figure 5A. [Figure 5C]This graph shows a significant decrease in the body weight-to-liver weight ratio due to DGAT2 silencing, following the experimental procedure described in Figure 5A. [Figure 5D] This graph shows the evaluation of hepatocyte death by measuring serum alanine aminotransferase (ALT) activity, following the experimental procedure described in Figure 5A. [Figure 5E] This graph shows the histological analysis of mouse liver tissue by hematoxylin and eosin (H&E) staining, following the experimental procedure described in Figure 5A, and demonstrates a reduction in hepatic fat accumulation in mice treated with GalNAc-siRNA1473. [Figure 5F] This graph shows the triglyceride concentration, diglyceride (DAG) concentration, and aliphatic acyl chain content in triglycerides (all measured by mass spectrometry) of the liver, following the experimental procedure described in Figure 5A. It shows a significant decrease in total liver triglycerides after DGAT2 silencing. [Figure 6A] This graph, part of a series of figures showing changes in de novo lipid biosynthesis in genetically obese NASH mice injected with GalNAc-NTC or GalNAc-1473, shows changes in de novo lipid biosynthesis related to changes in gene expression during DGAT2 knockdown. [Figure 6B] This image shows post-translational modifications of transcription factors involved in the expression of de novo lipid biosynthesis genes. [Figure 6C] This figure shows images and quantifications of the analysis of protein expression levels of transcription factors involved in de novo lipid biosynthesis gene expression. [Figure 7A] This graph shows the levels of phosphatidylcholine (A), phosphatidylethanolamine (B), and phosphatidylinositol (C) in a series of figures illustrating phospholipid levels in ob / ob mice with NASH injected with GalNAc-NTC or GalNAc-1473. [Figure 8]This graph shows the DGAT2 mRNA levels in 8-week-old male C57BL6 mice injected with GalNAc-NTC or GalNAc-1473. The mice were injected with 10 mg / kg of siRNA, and DGAT2 silencing in the kidneys, spleen, inguinal fat, epididymal fat, and liver was examined by qPCR. [Modes for carrying out the invention]

[0101] Novel DGAT2 target sequences are provided. Novel RNA molecules, including siRNA compounds, that target DGAT2 mRNA are also provided.

[0102] Unless otherwise specified, the nomenclature used herein in relation to cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein, as well as nucleic acid chemistry and hybridization, is well known and commonly used in the art. Unless otherwise specified, the methods and techniques provided herein are carried out in accordance with conventional methods well known in the art and as described in the various general and more specific references cited and discussed throughout this specification. Enzyme reactions and purification techniques are carried out as described herein, in accordance with the manufacturer's specifications or as commonly achieved in the art. The terminology used herein in relation to analytical chemistry, synthetic organic chemistry, and pharmaceutical / medical chemistry, as well as laboratory procedures and techniques, are well known and commonly used in the art. Standard techniques are used for the chemical synthesis, chemical analysis, pharmaceutical preparation, formulation, delivery, and treatment of patients.

[0103] Unless otherwise defined herein, scientific and technical terms used herein have the meanings generally understood by those skilled in the art. In the event of any potential ambiguity, the definitions provided herein shall prevail over any dictionary or external definitions. Unless otherwise required by context, singular terms shall include plural forms, and plural terms shall include singular forms. The use of "or" shall mean "and / or" unless otherwise stated. The use of the term "including," as well as other forms such as "include" and "included," is not limited to these.

[0104] To make this disclosure easier to understand, certain terms are defined first.

[0105] The term "nucleoside" refers to a molecule having a purine or pyrimidine base covalently linked to a ribose or deoxyribose sugar. Exemplary nucleosides include adenosine, guanosine, cytidine, uridine, and thymidine. Further exemplary nucleosides include inosine, 1-methylinosine, pseudouridine, 5,6-dihydrouridine, ribothymidine, 2N-methylguanosine, and N2,N2-dimethylguanosine (also known as "rare" nucleosides). The term "nucleotide" refers to a nucleoside having one or more phosphate groups attached to the sugar moiety within an ester linkage. Exemplary nucleotides include nucleoside monophosphates, diphosphates, and triphosphates. The terms "polynucleotide" and "nucleic acid molecule" are used interchangeably herein and refer to polymers of nucleotides linked together by phosphodiester or phosphorothioate linkages between 5' and 3' carbon atoms.

[0106] The terms “RNA,” “RNA molecule,” or “ribonucleic acid molecule” refer to polymers of ribonucleotides (e.g., 2, 3, 4, 5, 10, 15, 20, 25, 30, or more ribonucleotides). The terms “DNA,” “DNA molecule,” or “deoxyribonucleic acid molecule” refer to polymers of deoxyribonucleotides. DNA and RNA can be synthesized spontaneously (e.g., by DNA replication or DNA transcription, respectively). RNA can be modified after transcription. DNA and RNA can also be synthesized chemically. DNA and RNA can be single-stranded (i.e., ssRNA and ssDNA, respectively) or multi-stranded (e.g., double-stranded, i.e., dsRNA and dsDNA, respectively). “mRNA” or “messenger RNA” is single-stranded RNA that identifies the amino acid sequence of one or more polypeptide chains. This information is converted during protein synthesis when ribosomes bind to mRNA.

[0107] As used herein, the term “small interfering RNA” (“siRNA”) (also known in the art as “short interfering RNA”) refers to RNA (or RNA analogues) containing about 10 to 50 nucleotides (or nucleotide analogues) that can direct or mediate RNA interference. In certain embodiments, an siRNA contains about 15 to 30 nucleotides or nucleotide analogues, or about 16 to 25 nucleotides (or nucleotide analogues), or about 18 to 23 nucleotides (or nucleotide analogues), or about 19 to 22 nucleotides (or nucleotide analogues) (e.g., 19, 20, 21, or 22 nucleotides or nucleotide analogues). The term “short” siRNA refers to an siRNA containing about 21 nucleotides (or nucleotide analogues), e.g., 19, 20, 21, or 22 nucleotides. The term “long” siRNA refers to an siRNA containing about 24 to 25 nucleotides, e.g., 23, 24, 25, or 26 nucleotides. Short siRNAs may, in some cases, contain fewer than 19 nucleotides, e.g., 16, 17, or 18 nucleotides, provided that the short siRNA retains its ability to mediate RNAi. Similarly, long siRNAs may, in some cases, contain more than 26 nucleotides, provided that the longer siRNA retains its ability to mediate RNAi without further processing of the short siRNA, e.g., enzymatic processing.

[0108] The terms “nucleotide analog,” “modified nucleotide,” or “modified nucleotide” refer to non-standard nucleotides, such as ribonucleotides or deoxyribonucleotides, which do not exist in nature. Exemplary nucleotide analogs are modified at any position to alter the specific chemical properties of a nucleotide, while retaining the ability of the nucleotide analog to perform its intended function. Examples of nucleotide positions that can be derivatized include the 5-position, e.g., 5-(2-amino)propyluridine, 5-bromouridine, 5-propyneuridine, 5-propenyluridine; the 6-position, e.g., 6-(2-amino)propyluridine; and the 8-position of adenosine and / or guanosine, e.g., 8-bromoguanosine, 8-chloroguanosine, 8-fluoroguanosine. Furthermore, examples of nucleotide analogs include deazanucleotides, such as 7-deaza-adenosine; O- and N-modified nucleotides (e.g., alkylated nucleotides, such as N6-methyladenosine, or those known in the art); and other heterocyclic modified nucleotide analogs, such as those described in Herdewijn, Antisense Nucleic Acid Drug Dev., 2000 Aug.10(4):297-310.

[0109] Nucleotide analogs may also involve modifications to the sugar moiety of the nucleotide. For example, the 2'OH group may be substituted with a group selected from H, OR, R, F, Cl, Br, I, SH, SR, NH2, NHR, NR2, or COOR, where R is a substituted or unsubstituted C1-C6 alkyl, alkenyl, alkynyl, aryl, etc. Other possible modifications are described in U.S. Patents No. 5,858,988 and No. 6,291,438.

[0110] The phosphate group of a nucleotide can also be modified, for example, by substituting one or more oxygen atoms of the phosphate group with sulfur (e.g., a phosphorothioate), or by making other substitutions so that the nucleotide can perform its intended function. For example, see Eckstein, Antisense Nucleic Acid Drug Dev. 2000 Apr. 10(2):117-21, Rusckowski et al. Antisense Nucleic Acid Drug Dev. 2000 Oct. 10(5):333-45, Stein, Antisense Nucleic Acid Drug Dev. 2001 Oct. 11(5):317-25, Vorobjev et al. Antisense Nucleic Acid Drug Dev. 2001 Apr. 11(2):77-85, and U.S. Patent No. 5,684,143. The specific modifications referenced above (e.g., phosphate group modifications) reduce the hydrolysis rate of polynucleotides, including their analogs, for example, in vivo or in vitro.

[0111] The term "oligonucleotide" refers to a short polymer of nucleotides and / or nucleotide analogs.

[0112] The term “RNA analog” refers to a polynucleotide (e.g., a chemically synthesized polynucleotide) that has at least one modified or altered nucleotide compared to the corresponding unmodified or unaltered RNA, but retains the same or similar properties or functions as the corresponding unmodified or unaltered RNA. As described above, oligonucleotides may be linked by phosphodiester linkages that, compared to RNA molecules with phosphodiester linkages, result in a reduced hydrolysis rate of the RNA analog. For example, the nucleotides of an analog may include methylenediol, ethylenediol, oxymethylthio, oxyethylthio, oxycarbonyloxy, phosphorodiamidate, phosphoramidate, and / or phosphorothioate linkages. Some RNA analogs include sugar and / or skeletal-modified ribonucleotides and / or deoxyribonucleotides. Such alterations or alterations may further include the addition of non-nucleotide substances to the terminal(s) or internal(s) (one or more nucleotides) of the RNA. RNA analogs only need to be sufficiently similar to native RNA that has the ability to mediate RNA interference.

[0113] As used herein, the term “RNA interference” (“RNAi”) refers to the selective intracellular degradation of RNA. RNAi occurs naturally within cells and removes foreign RNA (e.g., viral RNA). Natural RNAi proceeds via fragments cleaved from free dsRNA, directing the degradation mechanism to other similar RNA sequences. Alternatively, RNAi can be initiated by humans, for example, to silence the expression of a target gene.

[0114] RNAi agents, such as RNA silencing agents, have a chain that is "sufficiently complementary to the target mRNA sequence in order to direct target-specific RNA interference (RNAi)." This means that the chain has a sequence sufficient to cause the destruction of the target mRNA by the RNAi mechanism or process.

[0115] As used herein, “isolated RNA” (e.g., “isolated siRNA” or “isolated siRNA precursor”) refers to an RNA molecule that, if produced by recombinant technology, is substantially free of other cell material or culture medium, and, if chemically synthesized, is substantially free of chemical precursors or other chemicals.

[0116] As used herein, the term “RNA silencing” refers to a group of sequence-specific regulatory mechanisms mediated by RNA molecules (e.g., RNA interference (RNAi), transcriptional gene silencing (TGS), post-transcriptional gene silencing (PTGS), querring, co-repression, and translational repression) that result in inhibition or “silencing” of the expression of the corresponding protein-coding gene. RNA silencing has been observed in many types of organisms, including plants, animals, and fungi.

[0117] The term “discriminative RNA silencing” refers to the ability of an RNA molecule to substantially inhibit the expression of a “first” or “target” polynucleotide sequence while not substantially inhibiting the expression of a “second” or “non-target” polynucleotide sequence, for example, when both polynucleotide sequences are present in the same cell. In certain embodiments, the target polynucleotide sequence corresponds to a target gene, and the non-target polynucleotide sequence corresponds to a non-target gene. In other embodiments, the target polynucleotide sequence corresponds to a target allele, and the non-target polynucleotide sequence corresponds to a non-target allele. In certain embodiments, the target polynucleotide sequence is a DNA sequence encoding a regulatory region (e.g., a promoter or enhancer element) of the target gene. In other embodiments, the target polynucleotide sequence is the target mRNA encoded by the target gene.

[0118] The term "in vitro" has the meaning recognized in the art, including, for example, purified reagents or extracts, such as cell extracts. The term "in vivo" also has the meaning recognized by those skilled in the art, including, for example, living cells, such as immortalized cells, primary cells, cell lines, and / or cells within an organism.

[0119] As used herein, the term “transgene” refers to any nucleic acid molecule that is artificially inserted into a cell and becomes part of the genome of an organism that develops from the cell. Such a transgene may include a gene that is partially or completely heterologous (i.e., exotic) to the transgenic organism, or it may represent a gene that is homologous to the organism’s endogenous genes. “Transgene” also means a nucleic acid molecule containing one or more selected nucleic acid sequences, e.g., DNA, that encodes one or more manipulated RNA precursors and is expressed in a transgenic organism, e.g., an animal, which is either partially or completely heterologous (i.e., exogenous) to the transgenic animal, or homologous to the transgenic animal’s endogenous genes but designed to be inserted into the animal’s genome at a location different from the native genes. The transgene may include one or more promoters and any other DNA, e.g., introns, necessary for the expression of the selected nucleic acid sequence, all of which are operably ligated to the selected sequence, and may also include enhancer sequences.

[0120] Genes “involved” in a disease or disorder include genes whose normal or abnormal expression or function affects or causes a disease or disorder, or at least one symptom of a disease or disorder.

[0121] As used herein, the term “target gene” refers to a gene whose expression is substantially inhibited or “silenced.” This silencing can be achieved, for example, by cleaving the mRNA of the target gene or by silencing the RNA by translational repression of the target gene. The term “non-target gene” refers to a gene whose expression is not substantially silenced. In one embodiment, the polynucleotide sequences of the target gene and the non-target gene (e.g., the mRNA encoded by the target gene and the non-target gene) may differ by one or more nucleotides. In another embodiment, the target and non-target genes may differ by one or more polymorphisms (e.g., single nucleotide polymorphisms or SNPs). In yet another embodiment, the target and non-target genes may share less than 100% sequence identity. In yet another embodiment, the non-target gene may be a homolog (e.g., an ortholog or paralog) of the target gene.

[0122] As described herein, the term "DGAT2" refers to the gene encoding the enzyme diacylglycerol O-acyltransferase 2. DGAT2 catalyzes the covalent bonding of diacylglycerol to long-chain aliphatic acyl-CoA in the final step of triglyceride synthesis. The DGAT2 gene is located on chromosome 11q13.5, consists of 9 exons, and is primarily expressed in the liver and white adipose tissue. The DGAT2 protein is 388 amino acids long and has a molecular weight of approximately 43,831 Da.

[0123] The phrase "to examine the function of genes in cells or organisms" refers to examining or studying the resulting expression, activity, function, or phenotype.

[0124] As used herein, the term “RNA silencing agent” refers to RNA capable of inhibiting or “silencing” the expression of a target gene. In certain embodiments, RNA silencing agents can prevent the complete processing of mRNA molecules (e.g., complete translation and / or expression) through a post-transcriptional silencing mechanism. Examples of RNA silencing agents include small (<50 b.p.), non-coding RNA molecules, such as double-stranded RNAs containing paired strands, and precursor RNAs capable of generating such small non-coding RNAs. Exemplary RNA silencing agents include siRNA, miRNA, siRNA-like double-stranded RNAs, antisense oligonucleotides, GAPMER molecules, and dual-function oligonucleotides, as well as their precursors. In one embodiment, RNA silencing agents can induce RNA interference. In another embodiment, RNA silencing agents can mediate translational repression.

[0125] As used herein, the term “rare nucleotide” refers to naturally occurring nucleotides that occur infrequently, such as naturally occurring deoxyribonucleotides or ribonucleotides that do not occur infrequently, such as guanosine, adenosine, cytosine, or uridine. Examples of rare nucleotides include, but are not limited to, inosine, 1-methylinosine, pseudouridine, 5,6-dihydrouridine, ribothymidine, 2N-methylguanosine, and 2,2N,N-dimethylguanosine.

[0126] The term "engineered" indicates that the precursor or molecule is not found in nature, in that all or part of the nucleic acid sequence of the precursor or molecule is created or selected by humans, as in the case of an engineered RNA precursor or engineered nucleic acid molecule. Once created or selected, the sequence is replicated, translated, transcribed, or otherwise processed by intracellular mechanisms. Therefore, an RNA precursor produced intracellularly from a transgene containing an engineered nucleic acid molecule is an engineered RNA precursor.

[0127] As used herein, the term “microRNA” (“miRNA”) is also known in the art as “small temporal RNA” (“stRNA”) and refers to a small (e.g., 10 to 50 nucleotides) RNA that is genetically encoded (e.g., by the genomes of viruses, mammals, or plants) and can direct or mediate RNA silencing. “miRNA disorder” refers to a disease or disorder characterized by abnormal expression or activity of miRNA.

[0128] As used herein, the term “dual-functional oligonucleotide” refers to an RNA silencing agent having the formula TL-μ, where T is the mRNA targeting portion, L is the ligation portion, and μ is the miRNA mobilization portion. As used herein, the terms “mRNA targeting portion,” “targeting portion,” “mRNA targeting portion,” or “targeting portion” refer to a domain, portion, or region of a dual-functional oligonucleotide that is sufficiently sized and sufficiently complementary to a portion or region of mRNA selected or targeted for silencing (i.e., the portion has a sequence sufficient to capture the target mRNA).

[0129] As used herein, the terms “linking moiety” or “linking portion” refer to a domain, part, or region of an RNA silencing agent that covalently conjugates or links mRNA.

[0130] As used herein, the terms “miRNA recruiting moiety,” “miRNA targeting moiety,” or “miRNA recruiting portion” refer to a domain, moiety, or region of a dual-function oligonucleotide that is of sufficient size and complementarity to a moiety or region selected for or targeted for recruitment to a target mRNA.

[0131] As used herein, the term “antisense strand” of an RNA silencing agent, e.g., siRNA or RNA silencing agent, refers to a strand substantially complementary to a section of approximately 10–50 nucleotides, e.g., approximately 15–30 nucleotides, 16–25, 18–23, or 19–22 nucleotides, of the mRNA of the gene targeted for silencing. The antisense strand or first strand has a sequence that is sufficiently complementary to the desired target mRNA sequence to direct target-specific silencing, e.g., sufficiently complementary to cause disruption of the desired target mRNA by an RNAi mechanism or process (RNAi interference), or sufficiently complementary to cause translational repression of the desired target mRNA.

[0132] The terms “sense strand” or “second strand” of an RNA silencing agent, such as siRNA, refer to a strand complementary to the antisense strand or first strand. The antisense strand and sense strand can also be referred to as the first strand or second strand, where the first strand or second strand is complementary to the target sequence, and each second strand or first strand is complementary to the first strand or second strand. A miRNA double-stranded intermediate or siRNA-like double-stranded intermediate includes a miRNA strand that is sufficiently complementary to a section of approximately 10-50 nucleotides of the mRNA of the gene targeted for silencing, and a miRNA strand that is sufficiently complementary to form a double-stranded structure with the miRNA strand.

[0133] As used herein, the term “guide strand” refers to the strand of RNA silencing agent, such as a double-stranded siRNA or antisense strand of an siRNA sequence, that enters the RISC complex and directs the cleavage of the target mRNA.

[0134] As used herein, the term “asymmetry” refers to an unevenness in the binding strength or base pair strength between the ends of an RNA silencing agent (e.g., between the terminal nucleotides on the first strand or stem portion and the terminal nucleotides on the opposing second strand or stem portion), such as in the asymmetry of the double-stranded region of the RNA silencing agent (e.g., the stem of shRNA). This results in the 5' end of one strand of the double helix being more frequently in a transient unpaired state, e.g., a single-stranded state, than the 5' end of the complementary strand. This structural difference determines that one strand of the double helix is ​​preferentially incorporated into the RISC complex. The strand whose 5' end is less firmly paired with the complementary strand will preferentially be incorporated into RISC and mediate RNAi.

[0135] As used herein, the terms “bond strength” or “base pair strength” primarily refer to the strength of interactions between pairs of nucleotides (or nucleotide analogs) on opposing strands of an oligonucleotide double-strand (e.g., an siRNA double-strand), and between these nucleotides (or nucleotide analogs), such as through H bonds and van der Waals interactions.

[0136] As used herein, "5' end" refers to the 5' terminal nucleotide, for example, the 1 to approximately 5 nucleotides at the 5' end of an antisense strand, such as the 5' end of an antisense strand. As used herein, "3' end" refers to the region complementary to the 5' terminal nucleotide of a complementary antisense strand, for example, the 1 to approximately 5 nucleotide region, such as the 3' end of a sense strand.

[0137] As used herein, the term “destabilized nucleotide” refers to a first nucleotide or nucleotide analog that can form a base pair with a second nucleotide or nucleotide analog such that the base pair has a lower binding strength than a conventional base pair (i.e., a Watson-Crick base pair). In certain embodiments, the destabilized nucleotide can form a mismatch base pair with the second nucleotide. In other embodiments, the destabilized nucleotide can form a fluctuation base pair with the second nucleotide. In yet another embodiment, the destabilized nucleotide can form an ambiguous base pair with the second nucleotide.

[0138] As used herein, the term “base pair” refers to the interaction between pairs of nucleotides (or nucleotide analogs) on opposing strands of an oligonucleotide double helix (e.g., a double helix formed by the strands of an RNA silencing agent and a target mRNA sequence), primarily through nucleotide (or nucleotide analog) H bonds, van der Waals interactions, and other interactions. As used herein, the terms “bond strength” or “base pair strength” refer to the strength of a base pair.

[0139] As used herein, the term "mismatched base pair" refers to a base pair consisting of a non-complementary or non-Watson-Crick base pair that is not a normal complementary G:C, A:T, or A:U base pair. As used herein, the term "ambiguous base pair" (also known as a non-recognized base pair) refers to a base pair formed by a universal nucleotide.

[0140] As used herein, the term “universal nucleotide” (also known as “neutral nucleotide”) includes nucleotides (e.g., certain destabilized nucleotides) that have bases that do not significantly distinguish between bases on a complementary polynucleotide when forming base pairs (“universal bases” or “neutral bases”). Universal nucleotides are primarily hydrophobic molecules and can efficiently pack into antiparallel double-stranded nucleic acids (e.g., double-stranded DNA or RNA) through stacking interactions. The base portion of a universal nucleotide typically contains a nitrogen-containing aromatic heterocyclic moiety.

[0141] As used herein, the terms “sufficient complementarity” or “sufficient degree of complementarity” mean that the RNA silencing agent has sequences (e.g., in the antisense strand, mRNA targeting portion, or miRNA recruiting portion) sufficient to bind to the desired target and induce RNA silencing of the target mRNA, respectively.

[0142] As used herein, the term “translational repression” refers to the selective inhibition of mRNA translation. Spontaneous translational repression proceeds via miRNA cleaved from small hairpin RNA (shRNA) precursors. Both RNAi and translational repression are mediated by the RNA-induced silencing complex (RISC). Both RNAi and translational repression occur spontaneously or can be initiated by humans, for example, to silence the expression of a target gene.

[0143] Various methodologies of this disclosure include a step of comparing values, levels, features, properties, etc., with a “preferred control,” which is interchangeably referred to herein as “appropriate control.” A “preferred control” or “appropriate control” is any control or standard well known to those skilled in the art and useful for comparison purposes. In one embodiment, a “preferred control” or “appropriate control” is a value, level, feature, property, etc., determined before performing the RNAi methodology as described herein. For example, transcription rate, mRNA level, translation rate, protein level, biological activity, cellular characteristics or properties, genotype, phenotype, etc., can be determined before introducing the RNA silencing agent of this disclosure into cells or organisms. In another embodiment, a “preferred control” or “appropriate control” is a value, level, feature, property, etc., determined in cells or organisms, e.g., a control or, e.g., normal cells or organisms exhibiting normal traits. In yet another embodiment, a “preferred control” or “appropriate control” is a predefined value, level, feature, property, etc.

[0144] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which this disclosure pertains. Similar or equivalent methods and materials may be used in the implementation or testing of this disclosure, but suitable methods and materials are described below. All publications, patent applications, patents, and other references referenced herein are incorporated in their entirety by reference. In case of any conflict, this specification shall prevail, including definitions. In addition, materials, methods, and examples are illustrative and not intended to be limiting.

[0145] Various aspects of this disclosure are described in further detail in the following subsections.

[0146] I. Novel target sequences In certain exemplary embodiments, the RNA silencing agent of the Disclosure may target any one of the DGAT2 nucleic acid sequences SEQ ID NOs: 1 to 10 listed in Table 1. In certain exemplary embodiments, the RNA silencing agent of the Disclosure comprises a double-stranded RNA (dsRNA) molecule including a sense strand and an antisense strand, wherein the antisense strand includes a sequence substantially complementary to the DGAT2 nucleic acid sequences SEQ ID NOs: 1 to 10 listed in Table 1. Exemplary antisense and sense strands are listed in Tables 2 to 4.

[0147] The genomic sequences of each target sequence can be found, for example, in publicly available databases maintained by NCBI.

[0148] II. Design of AVA In some embodiments, the siRNA is designed as follows: First, a portion of the target gene (e.g., the DGAT2 gene described above), for example, one or more target sequences shown in Table 1, are selected. The cleavage of mRNA at these sites eliminates the need for translation of the corresponding protein. The antisense strand is designed based on the target sequence, and the sense strand is designed to be complementary to the antisense strand. Hybridization of the antisense and sense strands forms the siRNA double helix. The antisense strand contains approximately 19–25 nucleotides, e.g., 19, 20, 21, 22, 23, 24, or 25 nucleotides. In other embodiments, the antisense strand contains 20, 21, 22, or 23 nucleotides. The sense strand contains approximately 14–25 nucleotides, e.g., 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In other embodiments, the sense strand is 15 nucleotides. In certain embodiments, the sense strand is 18 nucleotides. In other embodiments, the sense strand is 20 nucleotides. However, those skilled in the art will understand that siRNAs having a length of less than 19 nucleotides or a length of more than 25 nucleotides can also function to mediate RNAi. Thus, siRNAs of such lengths are also within the scope of this disclosure, insofar as they retain the ability to mediate RNAi. Longer RNAi agents have been demonstrated to induce interferon or PKR responses in certain mammalian cells, which may be undesirable. In certain embodiments, the RNAi agents of this disclosure do not induce a PKR response (i.e., are sufficiently short in length). However, longer RNAi agents may be useful, for example, in cell types that cannot produce a PKR response, or in situations where the PKR response is downregulated or suppressed by alternative means.

[0149] Sense strand sequences can be designed so that the target sequence is essentially located in the center of the strand. By shifting the target sequence to an off-center position, the efficiency of siRNA cleavage may, in some cases, be reduced. Such compositions, i.e., less efficient compositions, may be desirable for use when off-silencing of wild-type mRNA is detected.

[0150] The antisense strand may be the same length as the sense strand and may contain complementary nucleotides. In one embodiment, the strands are perfectly complementary; that is, they have blunt ends when aligned or annealed. In another embodiment, the strands are aligned or annealed such that a 1, 2, 3, 4, 5, 6, 7, or 8 nucleotide overhang is generated; that is, the 3' end of the sense strand is 1, 2, 3, 4, 5, 6, 7, or 8 nucleotides longer than the 5' end of the antisense strand, and / or the 3' end of the antisense strand is 1, 2, 3, 4, 5, 6, 7, or 8 nucleotides longer than the 5' end of the sense strand. The overhang may contain (or consist of) nucleotides corresponding to the target gene sequence (or its complement). Alternatively, the overhang may contain (or consist of) deoxyribonucleotides, e.g., dT, or nucleotide analogs, or other suitable non-nucleotide substances.

[0151] To facilitate the entry of the antisense strand into RISC (and thus increase or improve the efficiency of target cleavage and silencing), the base pair strength between the 5' end of the sense strand and the 3' end of the antisense strand may be modified (decreased or reduced). These are described in detail below and are incorporated by this reference into U.S. Patents 7,459,547, 7,772,203 and 7,732,593, titled “Methods and Compositions for Controlling Efficacy of RNA Silencing” (filed June 2, 2003) and U.S. Patents 8,309,704, 7,750,144, 8,304,530, 8,329,892 and 8,309,705, titled “Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi” (filed June 2, 2003). In one embodiment of these aspects of the Disclosure, the base pair strength is low because there are fewer G:C base pairs between the 5' end of the first or antisense strand and the 3' end of the second or sense strand than there are between the 3' end of the first or antisense strand and the 5' end of the second or sense strand. In another embodiment, the base pair strength is low due to at least one mismatched base pair between the 5' end of the first or antisense strand and the 3' end of the second or sense strand. In certain exemplary embodiments, the mismatched base pair is selected from the group consisting of: G:A, C:A, C:U, G:G, A:A, C:C, and U:U. In another embodiment, the base pair strength is low due to at least one fluctuating base pair, e.g., G:U, between the 5' end of the first or antisense strand and the 3' end of the second or sense strand. In another embodiment, the base pair strength is low due to at least one base pair containing a rare nucleotide, e.g., inosine(I). In certain exemplary embodiments, the base pairs are selected from the group consisting of I:A, I:U, and I:C. In yet another embodiment, the base pair strength is lower due to at least one base pair containing a modified nucleotide.In certain exemplary embodiments, the modified nucleotide is selected from the group consisting of 2-amino-G, 2-amino-A, 2,6-diamino-G, and 2,6-diamino-A.

[0152] The design of suitable siRNAs for targeting the DGAT2 target sequences shown in Table 1 is described in detail below. siRNAs can be designed for any other target sequences found in the DGAT2 gene according to the exemplary teachings above. Furthermore, this technique is applicable to targeting any other target sequences, such as non-disease-causing target sequences.

[0153] To verify the effectiveness of siRNA in disrupting mRNA (e.g., DGAT2 mRNA), siRNA can be incubated with cDNA (e.g., DGAT2 cDNA) in an in vitro mRNA expression system based on Drosophila melanogaster. 32 Newly synthesized mRNA (e.g., DGAT2 mRNA) radiolabeled with 3P is detected by autoradiography on an agarose gel. The presence of cleaved mRNA indicates mRNA nuclease activity. Suitable controls include the omission of siRNA. Alternatively, a control siRNA is selected that has the same nucleotide composition as the selected siRNA but lacks significant sequence complementarity to the appropriate target gene. Such negative controls can be designed by randomly scrambling the nucleotide sequence of the selected siRNA. A homology search can be performed to confirm that the negative control lacks homology to any other gene in the appropriate genome. Furthermore, negative control siRNA can be designed by introducing one or more base mismatches into the sequence. The siRNA-mRNA complementation site that yields optimal mRNA specificity and maximum mRNA cleavage is selected.

[0154] III. RNAi agents This disclosure includes RNAi molecules such as siRNA molecules designed as described above. The siRNA molecules of this disclosure can be chemically synthesized, or transcribed in vitro from a DNA template, or in vivo from, for example, shRNA, or by cleaving a transcribed dsRNA template in vitro using recombinant human DICER enzyme to form a pool of 20, 21, or 23 bp double-stranded RNA-mediated RNAi. The siRNA molecules can be designed using any method known in the art.

[0155] In one embodiment, instead of the RNAi agent being an interfering ribonucleic acid, the RNAi agent can encode the aforementioned interfering ribonucleic acid. In other words, the RNAi agent can serve as a transcription template for an interfering ribonucleic acid. Therefore, the RNAi agents of this disclosure may also include small hairpin RNAs (shRNAs) and expression constructs engineered to express shRNAs. The transcription of shRNAs is thought to be initiated by the polymerase III (pol III) promoter and terminated at position 2 of the 4-5-thymine transcription termination site. Upon expression, shRNAs are thought to fold into a stem-loop structure with a 3' UU overhang. Subsequently, the ends of these shRNAs are processed, converting them into siRNA-like molecules of approximately 21-23 nucleotides (Brummelkamp et al., 2002; Lee et al., 2002, above; Miyagishi et al., 2002; Paddison et al., 2002, above; Paul et al., 2002, above; Sui et al., 2002, above; Yu et al., 2002, above. Further information on shRNA design and use can be found on the internet at the following addresses: katandin.cshl.org:9331 / RNAi / docs / BseRI-BamHI_Strategy.pdf and katandin.cshl.org:9331 / RNAi / docs / Web_version_of_PCR_strategy1.pdf).

[0156] Expression constructs in this disclosure include, but are not limited to, any construct suitable for use in a suitable expression system, and include, as known in the art, retroviral vectors, linear expression cassettes, plasmids, and viruses or virus-derived vectors. Such expression constructs may include one or more inducible promoters, RNA Pol III promoter systems, e.g., the U6 snRNA promoter or the H1 RNA polymerase III promoter, or other promoters known in the art. A construct may contain one or both strands of siRNA. An expression construct expressing both strands may also contain a loop structure linking both strands, or each strand may be transcribed separately from separate promoters within the same construct. Each strand may be transcribed from a separate expression construct (Tuschl, T., 2002, above).

[0157] Synthetic siRNA can be delivered to cells by methods known in the art, such as cationic liposome transfection and electroporation. One or more siRNAs can be expressed intracellularly from recombinant DNA constructs to obtain long-term suppression of a target gene (e.g., the DGAT2 gene) and to facilitate delivery under specific circumstances. Methods for expressing double-stranded siRNA intracellularly from recombinant DNA constructs to enable longer-term target gene suppression in cells are known in the art, such as mammalian Pol III promoter systems capable of expressing functional double-stranded siRNA (e.g., H1 or U6 / snRNA promoter systems (Tuschl, T., 2002, above) (Bagella et al., 1998; Lee et al., 2002, above; Miyagishi et al., 2002, above; Paul et al., 2002, above; Yu et al., 2002, above; Sui et al., 2002, above)). PolIII-mediated transcription termination occurs at a sequence of four consecutive T residues within the DNA template, providing a mechanism to terminate siRNA transcripts at specific sequences. siRNA is complementary to the target gene sequence in the 5'-3' and 3'-5' directions, and the two strands of siRNA can be expressed in the same construct or separate constructs. Hairpin-type siRNAs, driven by H1 or U6 snRNA promoters and expressed intracellularly, can inhibit the expression of target genes (Bagella et al., 1998; Lee et al., 2002, above; Miyagishi et al., 2002, above; Paul et al., 2002, above; Yu et al., 2002), above; Sui et al., 2002, above). Constructs containing siRNA sequences under the control of the T7 promoter also produce functional siRNA when co-transfected into cells with a vector expressing T7 RNA polymerase (Jacque et al., 2002, above).A single construct may include multiple sequences encoding siRNA, such as multiple regions of a DGAT2-encoding gene that target the same gene or multiple genes, and may be driven, for example, by another PolIII promoter site.

[0158] Animal cells express a series of non-coding RNAs called microRNAs (miRNAs), each approximately 22 nucleotides long. These can regulate gene expression at the post-transcriptional or translational level during animal development. One common characteristic of miRNAs is that they are entirely cleaved from a precursor RNA stem-loop of approximately 70 nucleotides, likely by the RNase III enzyme Dicer or its homolog. By substituting the stem sequence of the miRNA precursor with a sequence complementary to the target mRNA, vector constructs expressing the engineered precursor can be used to produce siRNA and initiate RNAi against specific mRNA targets in mammalian cells (Zeng et al., above, 2002). When expressed by a DNA vector containing a polymerase III promoter, microRNA-designed hairpins can perform gene expression silencing (McManus et al., 2002, above). MicroRNAs targeting polymorphisms may also be useful for blocking the translation of mutant proteins in the absence of siRNA-mediated gene silencing. Such applications may be useful, for example, in situations where a designed siRNA causes off-target silencing of wild-type proteins.

[0159] Viral delivery mechanisms can also be used to induce specific silencing of targeted genes by generating recombinant adenoviruses containing siRNA, for example, under the transcriptional regulation of the RNA Pol II promoter, via siRNA expression (Xia et al., 2002, see above). Infection of HeLa cells with these recombinant adenoviruses can reduce the expression of endogenous target genes. In vitro reduction of target gene expression can be achieved by injecting recombinant adenovirus vectors into transgenic mice expressing the target gene of siRNA. Ibid. In animal models, synthetic siRNA can be efficiently delivered to transplanted mouse embryos by whole-embryonic electroporation (Calegari et al., 2002). In adult mice, efficient delivery of siRNA can be achieved by "high-pressure" delivery techniques, which involve rapidly injecting a large volume of siRNA-containing solution into the animal's tail vein (within 5 seconds) (Liu et al., 1999, above; McCaffrey et al., 2002, above; Lewis et al., 2002). siRNA can also be delivered to animals using nanoparticles and liposomes. In certain exemplary embodiments, recombinant adeno-associated viruses (rAAVs) and their associated vectors can be used to deliver one or more siRNAs to cells, such as nerve cells (e.g., brain cells) (U.S. Patent Applications Nos. 2014 / 0296486, 2010 / 0186103, 2008 / 0269149, 2006 / 0078542, and 2005 / 0220766).

[0160] The nucleic acid compositions of this disclosure include both unmodified siRNA and modified siRNA, such as cross-linked siRNA derivatives or derivatives having non-nucleotide moieties linked to their 3' or 5' ends. By modifying siRNA derivatives in this way, it is possible to improve cell uptake or enhance the cell targeting activity of the resulting siRNA derivatives compared to the corresponding siRNA, and it is also useful for tracking siRNA derivatives within cells or improving the stability of siRNA derivatives compared to the corresponding siRNA.

[0161] As described herein, an engineered RNA precursor introduced into a cell or organism leads to the production of a desired siRNA molecule. Such siRNA molecule then associates with endogenous protein components of the RNAi pathway, binding to a specific mRNA sequence and targeting it for cleavage and disruption. In this way, the mRNA is targeted by the siRNA produced from the engineered RNA precursor and depleted from the cell or organism, thereby reducing the concentration of the protein encoded by that mRNA in the cell or organism. The RNA precursor is typically a nucleic acid molecule that either codes for one strand of dsRNA individually or for the entire nucleotide sequence of an RNA hairpin loop structure.

[0162] The nucleic acid compositions of this disclosure may be conjugated or conjugated to another portion such as nanoparticles, thereby improving the properties of the compositions, such as pharmacokinetic parameters such as absorption, efficacy, bioavailability and / or half-life. Conjugation can be achieved, for example, using the methods known in this technology, or the following methods: Lambert et al., Drug Deliv. Rev.:47(1),99-112(2001) (described on nucleic acids attached to polyalkylcyanoacrylate (PACA) nanoparticles); Fattal et al., J. Control Release 53(1-3):137-43(1998) (described on nucleic acids bound to nanoparticles); Schwab et al., Ann. Oncol. 5 Suppl. 4:55-8(1994) (described on nucleic acids linked to intercalating agents, hydrophobic groups, polycations, or PACA nanoparticles); and Godard et al., Eur. J. Biochem. 232(2):404-10(1995) (described on nucleic acids linked to nanoparticles).

[0163] The nucleic acid molecules of this disclosure can also be labeled using any method known in the art. For example, nucleic acid compositions can be labeled with fluorophores, such as Cy3, fluorescein, or rhodamine. Labeling can be carried out using a kit, such as the SILENCER® siRNA labeling kit (Ambion). Furthermore, siRNA can be labeled, for example, 3 H, 32 It can be radiolabeled using phosphate (P) or another suitable isotope.

[0164] Furthermore, since RNAi is thought to proceed via at least one single-stranded RNA intermediate, those skilled in the art will understand that ss-siRNA (e.g., the antisense strand of ds-siRNA) can also be designed (e.g., for chemosynthesis), generated (e.g., enzymatically), or expressed (e.g., from a vector or plasmid) as described herein, and utilized according to the claimed methodology. Furthermore, in invertebrates, RNAi can be effectively induced by long dsRNAs (e.g., dsRNAs of approximately 100–1000 nucleotides in length, e.g., approximately 200–500, e.g., approximately 250, 300, 350, 400, or 450 nucleotides in length) acting as effectors of RNAi (Brondani et al., Proc Natl Acad Sci USA. 2001 Dec. 4; 98(25): 14428-33. Epub 2001 Nov. 27.).

[0165] IV. Anti-DGAT2 RNA silencing agents In certain embodiments, the disclosure provides novel anti-DGAT2 RNA silencing agents (e.g., siRNA and antisense oligonucleotides), methods for constructing RNA silencing agents, and methods for using improved RNA silencing agents (or parts thereof) for RNA silencing of the DGAT2 protein (e.g., research and / or therapeutic methods). The RNA silencing agent comprises an antisense strand (or part thereof), the antisense strand having sufficient complementarity to the target DGAT2 mRNA to mediate an RNA-mediated silencing mechanism (e.g., RNAi).

[0166] In certain embodiments, siRNA compounds having one or any combination of the following properties are provided: (1) completely chemically stabilized (i.e., no unmodified 2'-OH residues); (2) asymmetric; (3) 11-21 base pair double heddle; (4) at least 50% 2'-methoxy modification, e.g., 70-100% 2'-methoxy modification, alternating patterns of chemically modified nucleotides (e.g., 2'-fluoro and 2'-methoxy modification) are also intended; and (5) single-stranded, fully phosphorothiolated 2-8 base tails. In certain embodiments, the number of phosphorothioate modifications varies from a total of 4 to 16. In certain embodiments, the number of phosphorothioate modifications varies from a total of 8 to 13.

[0167] In certain embodiments, the siRNA compounds described herein can be conjugated to a variety of targeting agents, including, but not limited to, cholesterol, docosahexaenoic acid (DHA), phenyltropane, cortisol, vitamin A, vitamin D, N-acetylgalactosamine (GalNac), and gangliosides.

[0168] Certain compounds of this disclosure having the structural properties described above may be referred to herein as “hsiRNA-ASP” (hydrophobically modified small interfering RNA characterized by a highly stabilized pattern). Furthermore, this hsiRNA-ASP pattern exhibits dramatically improved distribution through several tissues, including, but not limited to, the liver, placenta, kidney, and spleen, thereby enabling therapeutic interventions in these tissues.

[0169] The compounds of this disclosure can be described in the following aspects and embodiments.

[0170] In a first embodiment, this specification refers to a double-stranded RNA (dsRNA) comprising an antisense strand and a sense strand, where each strand has a 5' end and a 3' end. (1) The antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of sequence numbers 1 to 10; (2) The antisense chain contains at least 70% 2'-O-methyl modification; (3) The nucleotides at positions 2, 6, 14, and 16 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) The nucleotides from the 1-2 position to the 1-7 position from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) A portion of the antisense chain is complementary to a portion of the sense chain; (6) The sense chain contains at least 70% 2'-O-methyl modification; (7) The nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages. The above dsRNA is provided.

[0171] In another embodiment, this specification provides for a dsRNA comprising an antisense strand and a sense strand, each strand having a 5' end and a 3' end, (1) The antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of sequence numbers 1 to 10; (2) The antisense chain contains at least 70% 2'-O-methyl modification; (3) The nucleotides at positions 4, 5, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) The nucleotides from the 1-2 position to the 1-7 position from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) A portion of the antisense chain is complementary to a portion of the sense chain; (6) The sense chain contains 100% 2'-O-methyl modification; (7) The nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages. The above dsRNA is provided.

[0172] In another embodiment, this specification provides for a dsRNA comprising an antisense strand and a sense strand, each strand having a 5' end and a 3' end, (1) The antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of sequence numbers 1 to 10; (2) The antisense chain contains at least 70% 2'-O-methyl modification; (3) The nucleotides at positions 2, 4, 5, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) The nucleotides from the 1-2 position to the 1-7 position from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) A portion of the antisense chain is complementary to a portion of the sense chain; (6) The sense chain contains 100% 2'-O-methyl modification; (7) The nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages. The above dsRNA is provided.

[0173] In another embodiment, this specification provides for a dsRNA comprising an antisense strand and a sense strand, each strand having a 5' end and a 3' end, (1) The antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of sequence numbers 1 to 10; (2) The antisense chain contains at least 80% 2'-O-methyl modification; (3) The nucleotides at positions 2, 4, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) The nucleotides from the 1-2 position to the 1-7 position from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) A portion of the antisense chain is complementary to a portion of the sense chain; (6) The sense chain contains 80% 2'-O-methyl modification; (7) The nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages. The above dsRNA is provided.

[0174] In another embodiment, this specification provides for a dsRNA comprising an antisense strand and a sense strand, each strand having a 5' end and a 3' end, (1) The antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of sequence numbers 1 to 10; (2) The antisense chain contains at least 70% 2'-O-methyl modification; (3) The nucleotides at positions 2, 6, 14, 16, and 20 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) The nucleotides from the 1-2 position to the 1-7 position from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) A portion of the antisense chain is complementary to a portion of the sense chain; (6) The sense chain contains 70% 2'-O-methyl modification; (7) The nucleotides at positions 7 and 9-11 from the 3' end of the sense strand are not 2'-methoxyribonucleotides; (8) The nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages. The above dsRNA is provided.

[0175] In another embodiment, this specification provides for a dsRNA comprising an antisense strand and a sense strand, each strand having a 5' end and a 3' end, (1) The antisense strand contains a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of sequence numbers 1 to 10; (2) The antisense chain contains at least 70% 2'-O-methyl modification; (3) The nucleotides at positions 2, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) The nucleotides from the 1-2 position to the 1-7 position from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) A portion of the antisense chain is complementary to a portion of the sense chain; (6) The sense chain contains 70% 2'-O-methyl modification; (7) The nucleotides at positions 7, 10, and 11 from the 3' end of the sense strand are not 2'-methoxyribonucleotides; (8) The nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages. The above dsRNA is provided.

[0176] In another embodiment, the foregoing describes a dsRNA comprising an antisense strand and a sense strand, each strand having a 5' end and a 3' end, wherein (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand comprises at least 50% 2'-O-methyl modification; (3) the nucleotides at positions 2, 4, 6, 8, 10, 12, 14, and 16 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; and (4) the nucleotides at positions 1 to 2 from the 3' end of the antisense strand The dsRNA is provided wherein the nucleotides at positions 1-7 are linked to each other via phosphorothioate nucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains at least 65% 2'-O-methyl modification; (7) the nucleotides at positions 3, 7, 9, 11, and 13 from the 3' end of the sense strand are not 2'-methoxyribonucleotides; and (8) the nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0177] In another embodiment, the Specified Provision provides a dsRNA comprising an antisense strand and a sense strand, each strand having a 5' end and a 3' end, wherein (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs. 1 to 10; (2) the antisense strand comprises at least 85% 2'-O-methyl modification; (3) the nucleotides at positions 2, 14, and 20 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; (4) the nucleotides at positions 1-2 to 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate nucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand comprises at least 100% 2'-O-methyl modification; and (7) the nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0178] In another embodiment, the foregoing describes a dsRNA comprising an antisense strand and a sense strand, each strand having a 5' end and a 3' end, wherein (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs. 1 to 10; (2) the antisense strand comprises at least 75% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, 14, 16, and 20 from the 5' end of the antisense strand are not 2'-methoxyribonucleotides; and (4) the nucleotides at positions 1 to 2 from the 3' end of the antisense strand are 1 to 7 The dsRNA is provided wherein the nucleotides at the 1st position are linked to each other via phosphorothioate nucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains at least 75% 2'-O-methyl modification; (7) the nucleotides at positions 7, 9, 10, and 11 from the 3' end of the sense strand are not 2'-methoxy-ribonucleotides; and (8) the nucleotides at positions 1-2 from the 5' end of the sense strand are linked to each other via phosphorothioate nucleotide linkages.

[0179] In any of the above embodiments of the present disclosure, the antisense strand may have a nucleotide length of 20 or 21.

[0180] In any of the above embodiments of the present disclosure, the sense strand may have a length of 16, 18, 19, 20, or 21 nucleotides.

[0181] In certain embodiments of the dsRNA described above, the nucleotides from the 5' end to the 20th position of the antisense strand are not 2'-methoxyribonucleotides.

[0182] a) Design of an anti-DGAT2 siRNA molecule The siRNA molecule of the present invention is a double helix composed of a sense strand and a complementary antisense strand, the antisense strand being sufficiently complementary to the DGAT2 mRNA for mediating RNAi. In certain embodiments, the siRNA molecule has a nucleotide length of about 10 to 50 or more, i.e., each strand contains 10 to 50 nucleotides (or nucleotide analogs). In other embodiments, the siRNA molecule has a nucleotide length of about 15 to 30 in each strand, for example, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, where one of the strands is sufficiently complementary to the target region. In certain embodiments, the strands are arranged such that at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases are present at the ends of the strands that do not align (i.e., no complementary bases are produced in the opposing strands). This results in an overhang of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 residues occurring at one or both ends of the double helix when the chain is annealed.

[0183] Typically, siRNA can be designed using any method known in the art, for example, using the following protocol:

[0184] 1. The siRNA shall be specific to the target sequence, for example, the target sequence described in the Examples. The first strand shall be complementary to the target sequence, and the other strand shall be substantially complementary to the first strand. (See Examples for exemplary sense and antisense strands.) Exemplary target sequences are selected from any region of the target gene that results in potent gene silencing. Examples of target gene regions include, but are not limited to, the 5' untranslated region (5'-UTR), the 3' untranslated region (3'-UTR), the exons, or the introns. Cleavage of mRNA at these sites eliminates the need for translation of the corresponding DGAT2 protein. Target sequences from other regions of the DGAT2 gene are also suitable for targeting. The sense strand is designed based on the target sequence.

[0185] 2. The sense strand of the siRNA is designed based on the sequence of the selected target site. In certain embodiments, the sense strand contains approximately 15–25 nucleotides, e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides. In certain embodiments, the sense strand contains 15, 16, 17, 18, 19, or 20 nucleotides. In certain embodiments, the sense strand is 15 nucleotides long. In certain embodiments, the sense strand is 18 nucleotides long. In certain embodiments, the sense strand is 20 nucleotides long. However, those skilled in the art will understand that siRNAs having lengths less than 15 nucleotides or longer than 25 nucleotides can also function to mediate RNAi. Thus, siRNAs of such lengths are also within the scope of this disclosure, insofar as they retain the ability to mediate RNAi. Longer RNA silencing agents have been demonstrated to induce interferon or protein kinase R (PKR) responses in certain mammalian cells, which may be undesirable. In certain embodiments, the RNA silencing agents of this disclosure do not induce a PKR response (i.e., are sufficiently short in length). However, longer RNA silencing agents may be useful, for example, in cell types that cannot produce a PKR response, or in situations where the PKR response is downregulated or suppressed by alternative means.

[0186] The siRNA molecules of this disclosure have sufficient complementarity with the target sequence so that the siRNA can mediate RNAi. Generally, siRNA containing a nucleotide sequence sufficiently complementary to the target sequence portion of the target gene is intended to result in RISC-mediated cleavage of the target gene. Therefore, in certain embodiments, the antisense strand of the siRNA is designed to have a sequence sufficiently complementary to a portion of the target. For example, the antisense strand may have 100% complementarity with respect to the target site. However, 100% complementarity is not required. A greater than 80% identity between the antisense strand and the target RNA sequence is intended, e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or even 100% complementarity. This invention has the advantage of allowing for specific sequence modifications to enhance the efficiency and specificity of RNAi. In one embodiment, the antisense strand has 4, 3, 2, 1, or 0 mismatched nucleotides in a target region, such as a target region, where at least one base pair differs between the wild-type allele and the mutant allele. For example, the target region may contain a gain-of-function mutation, and the other strand may be identical or substantially identical to the first strand. Furthermore, siRNA sequences with small insertions or deletions of 1 or 2 nucleotides may also be effective in mediating RNAi. Alternatively, siRNA sequences with substitutions or insertions of nucleotide analogs may be effective in inhibition.

[0187] Sequence identity can be determined by sequence comparison and alignment algorithms known in the art. To determine the percentage of identity between two nucleic acid sequences (or two amino acid sequences), the sequences are aligned for optimal comparison (for example, gaps can be introduced into the first or second sequence for optimal alignment). Then, the nucleotides (or amino acid residues) at the corresponding nucleotide (or amino acid) positions are compared. If a position in the first sequence is occupied by the same residue as the corresponding position in the second sequence, the molecules are identical at that position. The percentage of identity between the two sequences corresponds to the number of identical positions shared by the sequences (i.e., % homology = number of identical positions / total number of positions × 100), and optionally, a penalty is given to the score for the number and / or length of introduced gaps.

[0188] The comparison of sequences and the determination of the percentage of identity between two sequences can be achieved using mathematical algorithms. In one embodiment, alignment is generated in specific parts of aligned sequences that have sufficient identity, but not in parts with a low degree of identity (i.e., local alignment). A non-restrictive example of a local alignment algorithm used for sequence comparison is the algorithm of Karlin and Altschul (1990) Proc.Natl.Acad.Sci.USA 87:2264-68, revised Karlin and Altschul (1993) Proc.Natl.Acad.Sci.USA 90:5873-77. Such an algorithm is incorporated into the BLAST program (version 2.0), Altschul, et al. (1990) J.Mol.Biol.215:403-10.

[0189] In another embodiment, the alignment is optimized by introducing appropriate gaps, and percentage identity is determined over the length of the aligned sequence (i.e., the gapped alignment). To obtain a gap alignment for comparison purposes, Gapped BLAST can be used as described in Altschul et al. (1997) Nucleic Acids Res. 25(17):3389-3402. In another embodiment, the alignment is optimized by introducing appropriate gaps, and percentage identity is determined over the entire length of the aligned sequence (i.e., global alignment). A non-restrictive example of a mathematical algorithm used for global sequence comparison is the algorithm by Myers and Miller, CABIOS (1989). Such algorithms are incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When using the ALIGN program to compare amino acid sequences, the PAM120 weight residue table, 12 gap length penalties, and 4 gap penalties can be used.

[0190] 3. The antisense or guide strand of an siRNA is routinely the same length as the sense strand and contains complementary nucleotides. In one embodiment, the guide and sense strands are perfectly complementary; that is, the strands are blunt-ended when aligned or annealed. In another embodiment, the siRNA strands may be paired to have 1-7 (e.g., 2, 3, 4, 5, 6, or 7) or 1-4 3' overhangs, e.g., 2, 3, or 4 nucleotides. The overhangs may contain (or consist of) nucleotides corresponding to the target gene sequence (or its complement). Alternatively, the overhangs may contain (or consist of) deoxyribonucleotides, e.g., dT, or nucleotide analogs, or other suitable non-nucleotide substances. Thus, in another embodiment, the nucleic acid molecule may have a 2-nucleotide 3' overhang, such as TT. The overhang nucleotides may be either RNA or DNA. As described above, it is desirable to select a target region where the mutant:wild-type mismatch is a purine:purine mismatch.

[0191] 4. By using any method known in the art, potential targets can be compared to appropriate genome databases (human, mouse, rat, etc.) to eliminate the need to consider any target sequences that have significant homology with other coding sequences. One such sequence homology search method is known as BLAST and is available on the National Center for Biotechnology Information website.

[0192] 5. Select one or more sequences that meet the evaluation criteria.

[0193] General information regarding the design and use of siRNA can be found in "The siRNA User Guide," available on the website of The Max-Plank-Institut fur Biophysikalische Chemie.

[0194] Alternatively, siRNA can be functionally defined as a nucleotide sequence (or oligonucleotide sequence) that can hybridize to a target sequence (e.g., hybridize at 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, and 50 °C or 70 °C for 12 - 16 hours and then wash). Additional hybridization conditions include hybridization at 70 °C in 1xSSC or 50 °C in 1xSSC, hybridization in 50% formamide, followed by washing at 70 °C in 0.3xSSC, or hybridization at 70 °C in 4xSSC or 50 °C in 4xSSC, 50% formamide, followed by washing at 67 °C in 1xSSC. The hybridization temperature of a hybrid predicted to be less than 50 base pairs in length should be 5 - 10 °C lower than the melting temperature (T m ) of the hybrid. Here, T m is determined according to the following formula. For hybrids less than 18 base pairs in length, T m (°C) = 2 (# of A + T bases) + 4 (# of G + C bases). For hybrids 18 - 49 base pairs in length, T m (°C) = 81.5 + 16.6(log10[Na+]) + 0.41(%G + C) - (600 / N) (where N is the number of bases in the hybrid and [Na+] is the concentration of sodium ions in the hybridization buffer ([Na + = 0.165 M for 1xSSC). Additional examples of stringency conditions for polynucleotide hybridization are described in Sambrook, J., E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters 9 and 11, and Current Protocols in Molecular Biology, 1995, F. M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3 - 6.4, which are incorporated herein by reference.

[0195] Negative control siRNAs should have the same nucleotide composition as the selected siRNA, but lack significant sequence complementarity with the appropriate genome. Such negative controls can be designed by randomly scrambling the nucleotide sequence of the selected siRNA. Homology searches can be performed to confirm that the negative control lacks homology to any other gene in the appropriate genome. Furthermore, negative control siRNAs can be designed by introducing one or more base mismatches into the sequence.

[0196] 6. To verify the effectiveness of siRNA in disrupting mRNA (e.g., wild-type or mutant DGAT2 mRNA), siRNA can be incubated with target cDNA (e.g., DGAT2 cDNA) in an in vitro mRNA expression system based on Drosophila melanogaster. 32 A newly synthesized target mRNA (e.g., DGAT2 mRNA) radiolabeled with 3P is detected by autoradiography on an agarose gel. The presence of cleaved target mRNA indicates mRNA nuclease activity. Suitable controls include the omission of siRNA and the use of non-target cDNA. Alternatively, a control siRNA is selected that has the same nucleotide composition as the selected siRNA but does not have significant sequence complementarity to the appropriate target gene. Such negative controls can be designed by randomly scrambling the nucleotide sequence of the selected siRNA. Homology searches can be performed to confirm that the negative control lacks homology to any other gene in the appropriate genome. Furthermore, negative control siRNA can be designed by introducing one or more base mismatches into the sequence.

[0197] Anti-DGAT2 siRNA can be designed to target any of the target sequences described above. The siRNA comprises an antisense strand that is sufficiently complementary to the target sequence to mediate the silencing of the target sequence. In certain embodiments, the RNA silencing agent is siRNA.

[0198] In certain embodiments, the siRNA comprises a sense strand and an antisense strand containing the sequences shown in Tables 2-4.

[0199] The siRNA-mRNA complementation site that provides optimal mRNA specificity and maximum mRNA cleavage is selected.

[0200] b) siRNA-like molecule The siRNA-like molecules of this disclosure have a sequence that is "sufficiently complementary" to the target sequence of DGAT2 mRNA (i.e., a sequence-containing strand) to direct gene silencing by RNAi or translational repression. The siRNA-like molecules are designed in the same manner as siRNA molecules, but the degree of sequence identity between the sense strand and the target RNA approximates that is observed between miRNA and its target. Generally, when the degree of sequence identity between the miRNA sequence and the corresponding target gene sequence decreases, the tendency for post-transcriptional gene silencing to be mediated by translational repression rather than RNAi increases. Therefore, in another embodiment where post-transcriptional gene silencing by translational repression of the target gene is desired, the miRNA sequence has partial complementarity with the target gene sequence. In certain embodiments, the miRNA sequence has partial complementarity with one or more short sequences (complementary sites) dispersed within the target mRNA (e.g., within the 3'UTR of the target mRNA) (Hutvagner and Zamore, Science, 2002; Zeng et al., Mol. Cell, 2002; Zeng et al., RNA, 2003; Doench et al., Genes & Dev., 2003). Because the translational repression mechanism is cooperative, in certain embodiments, multiple complementary sites (e.g., 2, 3, 4, 5, or 6) may be targeted.

[0201] The ability of an siRNA-like double-stranded molecule to mediate RNAi or translational repression can be predicted by the distribution of non-identical nucleotides between the target gene sequence and the nucleotide sequence of the silencing agent in the complementary region. In one embodiment where gene silencing by translational repression is desired, at least one non-identical nucleotide is present in the central part of the complementary region such that the double helix formed by the miRNA guide strand and the target mRNA contains a central "bulge" (Doench JG et al., Genes & Dev., 2003). In another embodiment, 2, 3, 4, 5, or 6 consecutive or non-identical nucleotides are introduced. The non-identical nucleotides may be selected to form fluctuating base pairs (e.g., G:U) or mismatch base pairs (G:A, C:A, C:U, G:G, A:A, C:C, U:U). In a further embodiment, the "bulge" is centered on the nucleotides at positions 12 and 13 from the 5' end of the miRNA molecule.

[0202] c) Small hairpin RNA (shRNA) molecules In certain characteristic embodiments, the present disclosure provides shRNAs capable of mediating highly selective RNA silencing of DGAT2 target sequences. In contrast to siRNAs, shRNAs mimic the natural precursors of microRNAs (miRNAs) and enter the gene silencing pathway at the top. For this reason, shRNAs are thought to more efficiently mediate gene silencing by being supplied throughout the entire natural gene silencing pathway.

[0203] miRNAs are non-coding RNAs of approximately 22 nucleotides that can regulate gene expression at the post-transcriptional or translational level during plant and animal development. One common characteristic of miRNAs is that they are all cleaved from a precursor RNA stem-loop of approximately 70 nucleotides, called pre-miRNA, likely by the RNase type III enzyme Dicer or its homolog. Naturally occurring miRNA precursors (pre-miRNAs) generally have a single strand that forms a double-stranded stem containing two complementary parts, and a loop connecting the two parts of the stem. In a typical pre-miRNA, the stem contains one or more bulges, e.g., extra nucleotides that create a single nucleotide “loop” within a part of the stem, and / or one or more unpaired nucleotides that create a gap in the mutual hybridization of the two parts of the stem. The small hairpin RNAs or engineered RNA precursors of this application are artificial constructs based on these naturally occurring pre-miRNAs and have been engineered to deliver a desired RNA silencing agent (e.g., siRNA of this disclosure). shRNA is formed by substituting the pre-miRNA stem sequence with a sequence complementary to the target mRNA. shRNA is processed throughout the cell's gene silencing pathway, thereby efficiently mediating RNAi.

[0204] The necessary elements of an shRNA molecule include a first and a second portion that have sufficient complementarity to anneal or hybridize to form a double-stranded or double-stranded stem portion. The two portions do not need to be completely or perfectly complementary. The first and second “stem” portions are joined by a portion having sequences that are not sufficiently sequence-complementary to anneal or hybridize to the other portion of the shRNA. This latter portion is called the “loop” portion within the shRNA molecule. The shRNA molecule is processed to produce siRNA. The shRNA may also contain one or more bulges, i.e., extra nucleotides that create small nucleotide “loops,” e.g., 1, 2, or 3 nucleotide loops, within the stem portion. The stem portions may be of the same length, or some may contain overhangs of, for example, 1 to 5 nucleotides. Overhang nucleotides may include, for example, uracil (U), e.g., all U. Such U is specifically encoded by thymidine (T) in the shRNA coding DNA, which signals the termination of transcription.

[0205] In the shRNA (or engineered precursor RNA) of this disclosure, a portion of the double-stranded stem is a nucleic acid sequence complementary (or antisense) to the DGAT2 target sequence. In certain embodiments, one strand of the shRNA stem portion is sufficiently complementary (e.g., antisense) to the target RNA (e.g., mRNA) sequence and mediates the degradation or cleavage of the target RNA via RNA interference (RNAi). Thus, the engineered RNA precursor comprises a double stem having two portions and a loop connecting the two stem portions. The antisense portion may be at the 5' or 3' end of the stem. The shRNA stem portion is about 15 to about 50 nucleotides long. In certain embodiments, the two stem portions are about 18 or 19 to about 21, 22, 23, 24, 25, 30, 35, 37, 38, 39, or 40 or more nucleotides long. In certain embodiments, the length of the stem portion is 21 nucleotides or more. When used in mammalian cells, the stem length should be less than approximately 30 nucleotides to avoid inducing nonspecific responses such as the interferon pathway. In non-mammalian cells, the stem may exceed 30 nucleotides. In fact, the stem may contain much larger sections complementary to the target mRNA (up to the entire mRNA, and including the entire mRNA).

[0206] The two parts of a double stem must be sufficiently complementary to hybridize and form a double stem. Therefore, the two parts may, but do not, be completely or perfectly complementary. Furthermore, the two stem parts may be the same length, or one part may contain an overhang of 1, 2, 3, or 4 nucleotides. The overhanging nucleotide may contain, for example, uracil (U), or all U. Loops in shRNA or engineered RNA precursors may differ from the native pre-miRNA sequence by modifying the loop sequence to increase or decrease the number of paired nucleotides, or by replacing all or part of the loop sequence with a tetraloop or other loop sequence. Therefore, loops in shRNA or engineered RNA precursors may have 2, 3, 4, 5, 6, 7, 8, 9, or more nucleotide lengths, for example, 15 or 20 or more.

[0207] Loops within shRNA or engineered RNA precursors may differ from native pre-miRNA sequences by modifying the loop sequence to increase or decrease the number of paired nucleotides, or by replacing all or part of the loop sequence with tetraloops or other loop sequences. Therefore, loop portions within shRNA can be approximately 2 to approximately 20 nucleotides long, i.e., approximately 2, 3, 4, 5, 6, 7, 8, 9, or more, for example, 15 or 20 nucleotides, or more. In certain embodiments, the loop consists of or includes a “tetraloop” sequence. Exemplary tetraloop sequences include, but are not limited to, the sequences GNRA (wherein N is any nucleotide and R is a purine nucleotide), GGGG, and UUUU.

[0208] In certain embodiments, the shRNA of the present application comprises the sequence of the desired siRNA molecule described above. In other embodiments, the sequence of the antisense portion of the shRNA can be designed essentially as described above, or more generally, by selecting a sequence of 18, 19, 20, 21 nucleotides, or longer, from within the target RNA (e.g., DGAT2 mRNA), for example, from a region of 100-200 or 300 nucleotides upstream or downstream of the translation start site. Generally, the sequence can be selected from any portion of the target RNA (e.g., mRNA), such as the 5'UTR (untranslated region), coding sequence, or 3'UTR. This sequence can optionally follow immediately after a region of the target gene containing two adjacent AA nucleotides. The last two nucleotides of the nucleotide sequence can be selected to be UU. Using this approximately 21 nucleotide sequence, a portion of the double-stranded stem of the shRNA is constructed. This sequence can, for example, enzymatically replace the stem portion of the wild-type pre-miRNA sequence, or it can be included in the complete sequence that is synthesized. For example, DNA oligonucleotides can be synthesized that encode the entire stem-loop manipulated RNA precursor, or only the portion that is inserted into the double-stranded stem of the precursor, and a manipulated RNA precursor construct can be constructed from, for example, wild-type pre-miRNA using restriction enzymes.

[0209] The engineered RNA precursor contains approximately 21-22 nucleotide sequences of siRNA or siRNA-like double helix that are desired to be produced in vivo within the double-stranded stem. Therefore, the stem portion of the engineered RNA precursor contains at least 18 or 19 nucleotide pairs corresponding to the sequence of the exon portion of the gene whose expression is reduced or inhibited. Two 3' nucleotides adjacent to this region of the stem are selected to maximize siRNA production from the engineered RNA precursor and to maximize the effectiveness of the resulting siRNA when targeting the corresponding mRNA for RNAi-mediated translational repression or disruption, both in vivo and in vitro.

[0210] In certain embodiments, the shRNAs of this disclosure include miRNA sequences, optionally more preferably terminally modified miRNA sequences, to enhance entry into RISC. The miRNA sequences may be similar to or identical to any naturally occurring miRNA sequence (e.g., The miRNA Registry; Griffiths-Jones S, Nuc. Acids Res., 2004). To date, more than 1,000 naturally occurring miRNAs have been identified, and together they are thought to represent about 1% of all predicted genes in the genome. Many naturally occurring miRNAs are clustered together in the introns of pre-mRNA and can be identified in silico using homology-based searches (Pasquinelli et al., 2000; Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001) or computer algorithms that predict the ability of candidate miRNA genes to form stem-loop structures with pre-mRNA (e.g., MiRScan, MiRSeeker) (Grad et al., Mol. Cell., 2003; Lim et al., Genes Dev., 2003; Lim et al., Science, 2003; Lai EC et al., Genome Bio., 2003). Online registries provide searchable databases of all publicly available miRNA sequences (The miRNA Registry, Sanger Institute website; Griffiths-Jones S, Nuc. Acids Res., 2004).Exemplary natural miRNAs include lin-4, let-7, miR-10, mirR-15, miR-16, miR-168, miR-175, miR-196 and their homologs, as well as other natural miRNAs of human origin and those of specific model organisms, such as Drosophila melanogaster, Caenorhabditis elegans, zebrafish, Arabidopsis thalania, Mus musculus, and Rattus norvegicus (described in PCT International Publication No. WO03 / 029459).

[0211] Naturally occurring miRNAs are expressed in vivo by endogenous genes and processed from hairpin or stem-loop precursors (pre-miRNA or pri-miRNA) by Dicer or other RNAses (Lagos-Quintana et al., Science, 2001; Lau et al., Science, 2001; Lee and Ambros, Science, 2001; Lagos-Quintana et al., Curr. Biol., 2002; Mourelatos et al., Genes Dev., 2002; Reinhart et al., Science, 2002; Ambros et al., Curr. Biol., 2003; Brennecke et al., 2003; Lagos-Quintana et al., RNA, 2003; Lim et al., Genes Dev., 2003; Lim et al., Science, 2003). miRNAs can exist transiently in vivo as double-stranded double helixes, but only one strand is incorporated into the RISC complex to direct gene silencing. Certain miRNAs, such as plant miRNAs, have complete or near-complete complementarity with their target mRNAs and therefore directly cleave the target mRNA. Other miRNAs have incomplete complementarity with their target mRNAs and therefore directly repress the translation of the target mRNA. The degree of complementarity between the miRNA and its target mRNA is thought to determine its mechanism of action. For example, complete or near-complete complementarity between the miRNA and its target mRNA predicts a cleavage mechanism (Yekta et al., Science, 2004), while incomplete complementarity predicts a translation repression mechanism. In certain embodiments, the miRNA sequence is a naturally occurring miRNA sequence whose abnormal expression or activity correlates with miRNA dysfunction.

[0212] d) Dual-function oligonucleotide tethering factors In other embodiments, the RNA silencing agents of this disclosure include dual-function oligonucleotide tethering factors useful for intercellular recruitment of miRNAs. Animal cells express a set of miRNAs, which are non-coding RNAs of about 22 nucleotides that can regulate gene expression at the post-transcriptional or translational level. Dual-function oligonucleotide tethering factors can suppress the expression of genes involved in processes such as atherosclerosis by binding miRNAs bound to RISC and recruiting them to target mRNAs. The use of oligonucleotide tethering factors offers several advantages over existing techniques for suppressing the expression of specific genes. First, the methods described herein allow endogenous molecules (often abundant), miRNAs, to mediate RNA silencing. Thus, the methods described herein eliminate the need to introduce exogenous molecules (e.g., siRNA) to mediate RNA silencing. Second, the RNA silencing agents and their binding portions (e.g., oligonucleotides, e.g., 2'-O-methyloligonucleotides) can be stabilized and made resistant to nuclease activity. As a result, the tethering factors of this disclosure can be designed for direct delivery, eliminating the need for indirect delivery (e.g., viruses) of precursor molecules or plasmids designed to produce the desired agent within the cell. Thirdly, the tethering factors and their respective portions can be designed to fit specific mRNA sites and specific miRNAs. The design may be cell and gene product specific. Fourthly, in the methods disclosed herein, the mRNA remains intact, allowing those skilled in the art to use the cell's own mechanisms to block protein synthesis with short pulses. Consequently, these RNA silencing methods are highly regulated.

[0213] The dual-function oligonucleotide tethering factors ("tethering factors") of this disclosure are designed to recruit miRNAs (e.g., endogenous cellular miRNAs) to target mRNAs to induce regulation of a gene of interest. In certain embodiments, the tethering factor has the formula TL-μ, where T is an mRNA targeting portion, L is a ligation portion, and μ is a miRNA recruitment portion. Any one or more portions may be double-stranded. In certain embodiments, each portion is single-stranded.

[0214] The portions within the tethering element can be positioned or ligated as shown in formula TL-μ (5' to 3' direction) (i.e., the 3' end of the targeting portion ligated to the 5' end of the ligation portion and the 3' end of the ligation portion ligated to the 5' end of the miRNA mobilization portion). Alternatively, these portions can be positioned or ligated within the tethering element as follows: μ-TL (i.e., the 3' end of the miRNA mobilization portion ligated to the 5' end of the ligation portion, and the 3' end of the ligation portion ligated to the 5' end of the targeting portion).

[0215] The mRNA targeting moiety, T, described above, can capture a specific target mRNA. According to this disclosure, since the expression of the target mRNA is undesirable, translational repression of the mRNA is desired. The mRNA targeting moiety is sized to effectively bind to the target mRNA. The length of the targeting moiety varies considerably, partly depending on the length of the target mRNA and the degree of complementarity between the target mRNA and the targeting moiety. In various embodiments, the targeting moiety is less than about 200, 100, 50, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, or 5 nucleotides long. In certain embodiments, the targeting moiety is about 15 to about 25 nucleotides long.

[0216] As described above, the miRNA recruiting portion, μ, can associate with miRNA. According to the present invention, the miRNA can be any miRNA capable of repressing a target mRNA. Mammals have been reported to have more than 250 endogenous miRNAs (Lagos-Quintana et al. (2002) Current Biol. 12:735-739; Lagos-Quintana et al. (2001) Science 294:858-862; and Lim et al. (2003) Science 299:1540). In various embodiments, the miRNA can be any miRNA recognized in the art.

[0217] The ligation site, L, is any agent that can ligate the targeting site so as to maintain the activity of the targeting site. The ligation site may be an oligonucleotide moiety containing a sufficient number of nucleotides so that the targeting agent can adequately interact with its respective target. The ligation site has little to no sequence homology to the cellular mRNA or miRNA sequence. Exemplary ligation sites include one or more 2'-O-methylnucleotides, such as 2'-β-methyladenosine, 2'-O-methylthymidine, 2'-O-methylguanosine, or 2'-O-methyluridine.

[0218] e) Gene silencing oligonucleotides In certain exemplary embodiments, gene expression (i.e., DGAT2 gene expression) can be regulated using oligonucleotide-based compounds comprising two or more single-stranded antisense oligonucleotides linked via their 5' ends, allowing for the presence of two or more accessible 3' ends, in order to effectively inhibit or reduce DGAT2 gene expression. Such linked oligonucleotides are also known as gene silencing oligonucleotides (GSOs) (see, for example, U.S. Patent No. 8,431,544, assigned to Idera Pharmaceuticals, Inc., which is incorporated herein by reference in its entirety for all purposes).

[0219] Linking at the 5' end of GSO is independent of other oligonucleotide linking and can occur directly via the 5', 3', or 2' hydroxyl group, or indirectly via a non-nucleotide linker or nucleoside, using either the 2' or 3' hydroxyl position of the nucleoside. Linking can also utilize a functionalized sugar or nucleic acid base of the 5' terminal nucleotide.

[0220] GSOs can contain two identical or different sequences conjugated at their 5'-5' ends via phosphodiesters, phosphorothioates, or non-nucleoside linkers. Such compounds may contain 15-27 nucleotides complementary to a specific portion of the target mRNA for downregulation of antisense of a gene product. GSOs containing identical sequences can bind to specific mRNAs via Watson-Crick hydrogen bond interactions and inhibit protein expression. GSOs containing different sequences can bind to two or more different regions of one or more mRNA targets and inhibit protein expression. Such compounds consist of heteronucleotide sequences complementary to the target mRNA, forming a stable double-strand structure via Watson-Crick hydrogen bonds. Under certain conditions, GSOs containing two free 3' ends (5'-5' attached antisense) can be more potent gene expression inhibitors than those with a single free 3' end or those without a free 3' end.

[0221] In some embodiments, the non-nucleotide linker is glycerol or formula HO--(CH2) o --CH(OH)--(CH2) p --OH is a glycerol homologue, where o and p are integers of 1 to about 6, 1 to about 4, or 1 to about 3, independently. In some other embodiments, the non-nucleotide linker is a derivative of 1,3-diamino-2-hydroxypropane. Some such derivatives have the formula HO--(CH2)m--C(O)NH--CH2--CH(OH)--CH2--NHC(O)--(CH2) m--It has an OH group, where m is an integer between 0 and approximately 10, 0 and approximately 6, 2 and approximately 6, or 2 and approximately 4.

[0222] Some non-nucleotide linkers allow for the attachment of three or more GSO components. For example, the non-nucleotide linker glycerol has three hydroxyl groups to which GSO components can be covalently attached. Thus, some oligonucleotide-based compounds of this disclosure contain two or more oligonucleotides linked to a nucleotide or non-nucleotide linker. Such oligonucleotides according to this disclosure are referred to as "branched".

[0223] In certain embodiments, the GSO is at least 14 nucleotides long. In certain exemplary embodiments, the GSO is 15–40 nucleotides long or 20–30 nucleotides long. Thus, the component oligonucleotides of the GSO can independently be 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides long.

[0224] These oligonucleotides can be prepared by methods recognized in the art, such as phosphoramidate or H-phosphonate chemistry, which can be carried out by manual or automated synthesizers. These oligonucleotides can also be modified in multiple ways without impairing their ability to hybridize to mRNA. Such modifications may include at least one internucleotide linkage of an oligonucleotide between the 5' end of one nucleotide and the 3' end of another nucleotide, which is an alkylphosphonate, phosphorothioate, phosphorodithioate, methylphosphonate, phosphate ester, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate hydroxyl, acetamidate, carboxymethyl ester, or a combination of these and other internucleotide linkages, where the phosphodiester linkage of the 5' nucleotide is substituted with any number of chemical groups.

[0225] V. Modified Anti-DGAT2 RNA Silencing Agent In certain embodiments of the present disclosure, the RNA silencing agent (or any portion thereof) of the present application can be modified as described above so that the activity of the agent is further improved. For example, the RNA silencing agent described in Section II above can be modified with any of the modifications described below. The modifications can, in part, act to further improve target discrimination, improve the stability of the agent (e.g., to prevent degradation), facilitate cellular uptake, improve target efficiency, improve the effectiveness of binding (e.g., to the target), improve patient tolerance to the agent, and / or reduce toxicity.

[0226] 1) Modifications for Improving Target Discrimination In certain embodiments, the RNA silencing agent of the present application can be substituted with destabilizing nucleotides to improve single nucleotide target discrimination (see U.S. Application No. 11 / 698,689, filed January 25, 2007, and U.S. Provisional Application No. 60 / 762,225, filed January 25, 2006. Both are incorporated herein by reference). Such modifications can be sufficient to abolish the specificity of the RNA silencing agent for non-target mRNAs (e.g., wild-type mRNAs) without an apparent effect on the specificity of the RNA silencing agent for the target mRNA (e.g., gain-of-function mutant mRNA).

[0227] In certain embodiments, the RNA silencing agent of the present application is modified by introducing at least one universal nucleotide into its antisense strand. A universal nucleotide contains a base moiety that can base pair indiscriminately with any of the four conventional nucleotide bases (e.g., A, G, C, U). Universal nucleotides are contemplated because they have only a relatively small effect on the stability of the RNA duplex or the duplex formed by the guide strand of the RNA silencing agent and the target mRNA. Exemplary universal nucleotides include those having an inosine base moiety or inosine-like base moiety selected from the group consisting of deoxyinosine (e.g., 2'-deoxyinosine), 7-deaza-2'-deoxyinosine, 2'-aza-2'-deoxyinosine, PNA-inosine, morpholino-inosine, LNA-inosine, phosphoramidate-inosine, 2'-O-methoxyethyl-inosine, and 2'-OMe-inosine. In certain embodiments, the universal nucleotide is an inosine residue or its natural analog.

[0228] In certain embodiments, the RNA silencing agent of the present disclosure is modified by introducing at least one destabilizing nucleotide within 5 nucleotides of a specificity-determining nucleotide (i.e., a nucleotide that recognizes a disease-associated polymorphism). For example, the destabilizing nucleotide can be introduced at a position within 5, 4, 3, 2, or 1 nucleotide of the specificity-determining nucleotide. In an exemplary embodiment, the destabilizing nucleotide is introduced at a position 3 nucleotides away from the specificity-determining nucleotide (i.e., such that there are 2 stabilizing nucleotides between the destabilizing nucleotide and the specificity-determining nucleotide). In an RNA silencing agent having two strands or strand portions (e.g., siRNA and shRNA), the destabilizing nucleotide can be introduced into the strand or strand portion that does not contain the specificity-determining nucleotide. In certain embodiments, the destabilizing nucleotide is introduced into the same strand or strand portion that contains the specificity-determining nucleotide.

[0229] 2) Modifications for enhancing efficacy and specificity In certain embodiments, the RNA silencing agents of this disclosure may be modified to easily enhance their efficacy and specificity in mediating RNAi in accordance with asymmetric design rules (see U.S. Patents 8,309,704, 7,750,144, 8,304,530, 8,329,892, and 8,309,705). Such modifications facilitate the entry of the antisense strand of siRNA (e.g., siRNA designed using the method of the present invention, or siRNA produced from shRNA) into RISC in a manner favorable to the sense strand. This allows the antisense strand to preferentially induce cleavage or translational repression of the target mRNA, thereby increasing or improving the efficiency of target cleavage and silencing. In certain embodiments, the asymmetry of the RNA silencing agent is enhanced by reducing the base pair strength between the antisense 5' end (AS5') and the sense 3' end (S3') of the RNA silencing agent, relative to the binding strength or base pair strength between the antisense 3' end (AS3') and the sense 5' end (S'5) of the RNA silencing agent.

[0230] In one embodiment, the asymmetry of the RNA silencing agent of the present application may be enhanced such that the number of G:C base pairs between the 5' end of the first or antisense strand and the 3' end of the sense strand portion is less than the number of G:C base pairs between the 3' end of the first or antisense strand and the 5' end of the sense strand portion. In another embodiment, the asymmetry of the RNA silencing agent of the present disclosure may be enhanced such that there is at least one mismatched base pair between the 5' end of the first or antisense strand and the 3' end of the sense strand portion. In a particular embodiment, the mismatched base pair is selected from the group consisting of: G:A, C:A, C:U, G:G, A:A, C:C, and U:U. In another embodiment, the asymmetry of the RNA silencing agent of the present disclosure may be enhanced such that there is at least one fluctuation base pair, for example, G:U, between the 5' end of the first or antisense strand and the 3' end of the sense strand portion. In another embodiment, the asymmetry of the RNA silencing agent of the Disclosure may be enhanced to include at least one base pair containing a rare nucleotide, such as inosine (I). In a particular embodiment, the base pair is selected from the group consisting of I:A, I:U, and I:C. In yet another embodiment, the asymmetry of the RNA silencing agent of the Disclosure may be enhanced to include at least one base pair containing a modified nucleotide. In a particular embodiment, the modified nucleotide is selected from the group consisting of 2-amino-G, 2-amino-A, 2,6-diamino-G, and 2,6-diamino-A.

[0231] 3) RNA silencing agents with improved stability The RNA silencing agent of this invention may be modified to improve its stability in serum or growth medium for cell culture. To improve stability, the 3'-residue may be stabilized against degradation and may be selected to consist of a purine nucleotide such as adenosine or guanosine nucleotide, for example. Alternatively, substitution of pyrimidine nucleotides with modification analogs, such as substitution of uridine with 2'-deoxythymidine, is acceptable and does not affect the efficiency of RNA interference.

[0232] In one embodiment, the present application features an RNA silencing agent comprising first and second strands, wherein the second strand and / or the first strand are modified by substituting internal nucleotides with modified nucleotides to improve in vivo stability compared to the corresponding unmodified RNA silencing agent. As defined herein, “internal” nucleotides are those located at any position other than the 5' or 3' end of a nucleic acid molecule, polynucleotide, or oligonucleotide. Internal nucleotides may be located within a single-stranded molecule or within a double-stranded or double-stranded molecule. In one embodiment, the sense strand and / or antisense strand are modified by the substitution of at least one internal nucleotide. In another embodiment, the sense strand and / or antisense strand are modified by at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more internal nucleotides. In another embodiment, the sense strand and / or antisense strand are modified by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more internal nucleotides. In yet another embodiment, the sense strand and / or antisense strand are modified by all substitutions of internal nucleotides.

[0233] In one embodiment, the present application features an RNA silencing agent in which at least 80% are chemically modified. In certain embodiments, the RNA silencing agent may be fully chemically modified, i.e., 100% of the nucleotides are chemically modified. In another embodiment, the present application features an RNA silencing agent comprising at least 80% chemically modified 2'-OH ribose groups. In certain embodiments, the RNA silencing agent comprises 2'-OH ribose groups that are chemically modified by about 80%, 85%, 90%, 95%, or 100%.

[0234] In certain embodiments, the RNA silencing agent may comprise at least one modified nucleotide analog. The nucleotide analog may be positioned in a location where target-specific silencing activity, such as RNAi-mediated activity or translational repression activity, is substantially unaffected, for example, in a region at the 5' and / or 3' ends of the siRNA molecule. Furthermore, the incorporation of the modified nucleotide analog may stabilize the ends.

[0235] Exemplary nucleotide analogs include sugar- and / or skeletal-modified ribonucleotides (i.e., modifications to the phosphate sugar backbone). For example, phosphodiester linkages in native RNA can be modified to include at least one nitrogen or sulfur heteroatom. In exemplary skeletal-modified ribonucleotides, the phosphodiester group bound to an adjacent ribonucleotide is replaced by a modifying group, for example, a phosphorothioate group. In exemplary sugar-modified ribonucleotides, the 2'OH- group is replaced by a group selected from H, OR, R, halo, SH, SR, NH2, NHR, NR2, or ON, where R is a C1-C6 alkyl, alkenyl, or alkynyl, and halo is F, Cl, Br, or I.

[0236] In certain embodiments, modifications are 2'-fluoro, 2'-amino, and / or 2'-thio modifications. Examples of modifications include 2'-fluorocytidine, 2'-fluorouridine, 2'-fluoroadenosine, 2'-fluoroguanosine, 2'-aminocytidine, 2'-aminouridine, 2'-aminoadenosine, 2'-aminoguanosine, 2,6-diaminopurine, 4-thiouridine, and / or 5-aminoallyluridine. In certain embodiments, the 2'-fluororibonucleotide is any uridine or cytidine. Additional exemplary modifications include 5-bromouridine, 5-iodouridine, 5-methylcytidine, ribothymidine, 2-aminopurine, 2'-aminobutyrylpyreneuridine, 5-fluorocytidine, and 5-fluorouridine. 2'-deoxynucleotides and 2'-Omenucleotides can also be used within the modified RNA silencing agent moiety of this disclosure. Additional modified residues include deoxy debases, inosine, N3-methyluridine, N6,N6-dimethyladenosine, pseudouridine, purine ribonucleosides, and ribavirin. In certain embodiments, the 2' portion is a methyl group, such that the linking portion is a 2'-O-methyl oligonucleotide.

[0237] In certain embodiments, the RNA silencing agent of the present invention comprises locked nucleic acid (LNA). The LNA contains sugar-modified nucleotides that are resistant to nuclease activity (highly stable) and have single-nucleotide recognition for mRNA (Elmen et al., Nucleic Acids Res., (2005), 33(1):439-447; Braasch et al. (2003) Biochemistry 42:7967-7975, Petersen et al. (2003) Trends Biotechnol 21:74-81). These molecules have modifiable 2'-O, 4'-C-ethylene-bridged nucleic acids, such as 2'-deoxy-2''-fluorouridine. Furthermore, the LNA increases the specificity of oligonucleotides by restricting the sugar moiety to a 3'-endoconformation, thereby pre-organizing the nucleotides for base pairing and raising the melting temperature of the oligonucleotides by about 10°C per nucleotide.

[0238] In another exemplary embodiment, the RNA silencing agent of the present invention comprises peptide nucleic acid (PNA). The PNA comprises modified nucleotides in which the sugar-phosphate moiety of the nucleotide is replaced with a neutral 2-aminoethylglycine moiety capable of forming a polyamide skeleton, thereby providing high resistance to nuclease digestion and conferring improved binding specificity to molecules (Nielsen, et al., Science, (2001), 254:1497-1500).

[0239] Nucleic acid base-modified ribonucleotides, i.e., ribonucleotides containing at least one non-naturally occurring nucleic acid base instead of naturally occurring ones, are also considered. The bases can be modified to block the activity of adenosine deaminase. Examples of modified nucleic acid bases include, but are not limited to, uridine and / or cytidine modified at position 5, e.g., 5-(2-amino)propyluridine, 5-bromouridine; adenosine and / or guanosine modified at position 8, e.g., 8-bromoguanosine; deazanucleotides, e.g., 7-deaza-adenosine; and O- and N-alkylated nucleotides, e.g., N6-methyladenosine. It should be noted that combinations of the above modifications are also possible.

[0240] In other embodiments, crosslinking can be used to alter the pharmacokinetics of RNA silencing agents, for example, to extend their half-life in the body. Therefore, this application includes RNA silencing agents having two complementary strands of nucleic acid, where the two strands are crosslinked. Thus, this application includes RNA silencing agents that are conjugated (e.g., at their 3' end) to another portion (e.g., a non-nucleic acid portion such as a peptide) or an organic compound (e.g., a dye). Modifying siRNA derivatives in this way can improve cellular uptake or enhance the cellular targeting activity of the resulting siRNA derivatives compared to the corresponding siRNA, and is useful for tracking siRNA derivatives within cells or improving the stability of siRNA derivatives compared to the corresponding siRNA.

[0241] Other exemplary modifications include: (a) modifications at the 2' position, e.g., providing a 2'OMe portion on U in a sense or antisense chain, or providing a 2'OMe portion in a 3' overhang, e.g., at the 3' terminus (where the 3' terminus means the 3' atom or at most 3' portion of the molecule, e.g., the most 3' P or 2' position as indicated by the context); (b) modifications of the phosphate backbone, e.g., by substitution of O with S, e.g., providing phosphorothioate modifications to U or A or both, particularly in an antisense chain; e.g., by substitution of O with S; (c) substitution of U with a C5 aminolinker; (d) substitution of A with G (the sequence change may, in certain embodiments, be located on the sense chain rather than the antisense chain); and (d) modifications at the 2', 6', 7', or 8' position. Exemplary embodiments are those in which one or more of these modifications are present on the sense but not on the antisense chain, or in which the antisense chain has few such modifications. Further exemplary modifications include the use of methylated P in the 3' overhang, for example at the 3' terminus; combinations of 2' modifications, for example providing a 2'OMe moiety and modifying the skeleton, for example substituting O with S, for example providing a phosphorothioate modification; or the use of methylated P in the 3' overhang, for example at the 3' terminus; modification with a 3' alkyl group; modification with debasal pyrrolidone in the 3' overhang, for example at the 3' terminus; or modification with naproxen, ibuprofen, or other moieties that inhibit degradation at the 3' terminus.

[0242] Highly modified RNA silencing agents In certain embodiments, the RNA silencing agent contains at least 80% chemically modified nucleotides. In certain embodiments, the RNA silencing agent is fully chemically modified, i.e., 100% of the nucleotides are chemically modified.

[0243] In certain embodiments, the RNA silencing agent is 2'-O-methyl rich, i.e., contains more than 50% 2'-O-methyl. In certain embodiments, the RNA silencing agent contains at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% 2'-O-methyl nucleotide content. In certain embodiments, the RNA silencing agent contains at least about 70% 2'-O-methyl nucleotide modification. In certain embodiments, the RNA silencing agent contains about 70% to about 90% 2'-O-methyl nucleotide modification. In certain embodiments, the RNA silencing agent is dsRNA including an antisense strand and a sense strand. In certain embodiments, the antisense strand contains at least about 70% 2'-O-methyl nucleotide modification. In certain embodiments, the antisense strand contains about 70% to about 90% 2'-O-methyl nucleotide modification. In certain embodiments, the sense strand contains at least about 70% 2'-O-methylnucleotide modifications. In certain embodiments, the sense strand contains about 70% to about 90% 2'-O-methylnucleotide modifications. In certain embodiments, the sense strand contains 100% 2'-O-methylnucleotide modifications.

[0244] 2'-O-methyl-rich RNA silencing agents and specific chemical modification patterns are further described in U.S. Patent Publication 2020 / 0087663A1 and U.S. SN 16 / 999,759 (filed August 21, 2020), each of which is incorporated herein by reference.

[0245] Internucleotide ligation modification In certain embodiments, at least one nucleotide linkage, subunit linkage, or nucleotide backbone is modified in the RNA silencing agent. In certain embodiments, all nucleotide linkages in the RNA silencing agent are modified. In certain embodiments, the modified nucleotide linkages include phosphorothioate nucleotide linkages. In certain embodiments, the RNA silencing agent includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 phosphorothioate nucleotide linkages. In certain embodiments, the RNA silencing agent includes 4 to 16 phosphorothioate nucleotide linkages. In certain embodiments, the RNA silencing agent includes 8 to 13 phosphorothioate nucleotide linkages. In certain embodiments, the RNA silencing agent is a dsRNA including an antisense strand and a sense strand, each including a 5' end and a 3' end. In certain embodiments, the nucleotides at positions 1 and 2 from the 5' end of the sense strand are linked to adjacent ribonucleotides via phosphorothioate nucleotide linkages. In certain embodiments, the nucleotides at positions 1 and 2 from the 3' end of the sense strand are linked to adjacent ribonucleotides via phosphorothioate nucleotide linkages. In certain embodiments, the nucleotides at positions 1 and 2 from the 5' end of the antisense strand are linked to adjacent ribonucleotides via phosphorothioate nucleotide linkages. In certain embodiments, the nucleotides at positions 1-2 and 1-8 from the 3' end of the antisense strand are linked to adjacent ribonucleotides via phosphorothioate nucleotide linkages. In certain embodiments, the nucleotides at positions 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, or 1-8 from the 3' end of the antisense strand are linked to adjacent ribonucleotides via phosphorothioate nucleotide linkages. In certain embodiments, the nucleotides at positions 1-2 and 1-7 from the 3' end of the antisense strand are linked to adjacent ribonucleotides via phosphorothioate nucleotide linkages.

[0246] In one aspect, the present disclosure provides a modified oligonucleotide having a 5' end and a 3' end and being complementary to a target, the modified oligonucleotide including a sense strand and an antisense strand, and at least one linking unit between modified subunits of formula (I):

Chemical formula

Chemical formula

[0247] In one embodiment of formula (I), when W is CH,

Chemical formula

[0248] In one embodiment of formula (I), when W is selected from the group consisting of O, OCH2, OCH, CH2,

Chemical formula

[0249] In one embodiment of formula (I), when Y is O - one of Z or W is not O.

[0250] In one embodiment of formula (I), Z is CH2 and W is CH2. In another embodiment, the modification subunit linkage of formula (I) is formula (II): [ka] This is a connection between modifying subunits.

[0251] In one embodiment of formula (I), Z is CH2 and W is O. In another embodiment, the inter-subunit linkage of formula (I) is formula (III): [ka] This is a connection between modifying subunits.

[0252] In one embodiment of formula (I), Z is O and W is CH2. In another embodiment, the inter-subunit linkage of formula (I) is formula (IV): [ka] This is a connection between modifying subunits.

[0253] In one embodiment of formula (I), Z is O and W is CH. In another embodiment, the modifying subunit linkage of formula (I) is formula V: [ka] This is a connection between modifying subunits.

[0254] In one embodiment of formula (I), Z is O and W is OCH2. In another embodiment, the modifying subunit linkage of formula (I) is formula VI: [ka] This is a connection between modifying subunits.

[0255] In one embodiment of formula (I), Z is CH2 and W is CH. In another embodiment, the modifying subunit linkage of formula (I) is formula VII: [ka] This is a connection between modifying subunits.

[0256] In one embodiment of formula (I), the base pair portion B is selected from the group consisting of adenine, guanine, cytosine, and uracil.

[0257] In one embodiment, the modified oligonucleotide is a modified siRNA complementary to a target, having a 5' end and a 3' end, and is incorporated into the siRNA, comprising a sense strand and an antisense strand, and at least one modified subunit linkage of any one or more of formulas (I), (II), (III), (IV), (V), (VI), or (VII).

[0258] In one embodiment, the modified oligonucleotide is a modified siRNA having a 5' end and a 3' end, complementary to the target, and comprising a sense strand and an antisense strand, wherein at least one of the compounds is of formula VIII: [ka] (In the formula, D is selected from the group consisting of O, OCH2, OCH, CH2, and CH; C is O - , OH, OR 1 NH - NH2, S - Selected from the group consisting of , and SH, A is selected from the group consisting of O and CH2; R 1 is a protecting group; [ka] This is a bond that is a double bond by choice; (The subunits are bridged by two optionally modified nucleosides.) The modified subunit links are incorporated into the siRNA.

[0259] In one embodiment, C is O - If that is the case, then either A or D is not O.

[0260] In one embodiment, D is CH2. In another embodiment, the modifying subunit linkage of formula VIII is formula (IX): [ka] This is a connection between modifying subunits.

[0261] In one embodiment, D is O. In another embodiment, the modifying subunit linkage of formula VIII is formula (X): [ka] This is a connection between modifying subunits.

[0262] In one embodiment, D is CH2. In another embodiment, the modifying subunit linkage of formula (VIII) is formula (XI): [ka] This is a connection between modifying subunits.

[0263] In one embodiment, D is CH. In another embodiment, the inter-subunit linkage of formula VIII is formula (XII): [ka] This is a modified inter-subunit connection.

[0264] In another embodiment, the modified inter-subunit linkage of formula (VII) is formula (XIV): [ka] It is a modified inter-subunit connection.

[0265] In one embodiment, D is OCH2. In another embodiment, the modifying subunit linkage of formula (VII) is formula (XIII): [ka] This is a modified inter-subunit connection.

[0266] In another embodiment, the modifying subunit linkage of formula (VII) is formula (XXa): [ka] This is a connection between modifying subunits.

[0267] In one embodiment of the modified siRNA linkage described above, each optionally modified nucleoside is independently selected from the group consisting of adenosine, guanosine, cytidine, and uridine.

[0268] In one exemplary embodiment of formula (I), W is O. In another embodiment, W is CH2. In yet another embodiment, W is CH.

[0269] In a particular exemplary embodiment of formula (I), X is OH. In another embodiment, X is OCH3. In yet another embodiment, X is halo.

[0270] In certain embodiments of formula (I), the modified siRNA does not contain a 2'-fluoro substituent.

[0271] In the embodiment of formula (I), Y is O - In another embodiment, Y is OH. In yet another embodiment, Y is OR. In yet another embodiment, Y is NH - In one embodiment, Y is NH2. In another embodiment, Y is S - In yet another embodiment, Y is SH.

[0272] In one embodiment of formula (I), Z is O. In another embodiment, Z is CH2.

[0273] In one embodiment, the modification subunit linkage is inserted between positions 1 and 2 of the antisense chain. In another embodiment, the modification subunit linkage is inserted between positions 6 and 7 of the antisense chain. In yet another embodiment, the modification subunit linkage is inserted between positions 10 and 11 of the antisense chain. In yet another embodiment, the modification subunit linkage is inserted between positions 19 and 20 of the antisense chain. In one embodiment, the modification subunit linkage is inserted between positions 5 and 6 and positions 18 and 19 of the antisense chain.

[0274] In an exemplary embodiment of the modified siRNA linkage of formula (VIII), C is O - In another embodiment, C is OH. In yet another embodiment, C is OR 1 In yet another embodiment, C is NH - In one embodiment, C is NH2. In another embodiment, C is S - In yet another embodiment, C is SH.

[0275] In an exemplary embodiment of the modified siRNA linkage of formula (VIII), A is O. In another embodiment, A is CH2. In yet another embodiment, C is OR 1 In yet another embodiment, C is NH - In one embodiment, C is NH2. In another embodiment, C is S - In yet another embodiment, C is SH.

[0276] In certain embodiments of the modified siRNA linker of formula (VIII), the optionally modified nucleoside is adenosine. In another embodiment of the modified siRNA linker of formula (VIII), the optionally modified nucleoside is guanosine. In certain embodiments of the modified siRNA linker of formula (VIII), the optionally modified nucleoside is cytidine. In certain embodiments of the modified siRNA linker of formula (VIII), the optionally modified nucleoside is uridine.

[0277] In the above embodiment of modified siRNA linkage, the linkage is inserted at positions 1-2 of the antisense strand. In another embodiment, the linkage is inserted at positions 6-7 of the antisense strand. In yet another embodiment, the linkage is inserted at positions 10-11 of the antisense strand. In yet another embodiment, the linkage is inserted at positions 19-20 of the antisense strand. In one embodiment, the linkage is inserted at positions 5-6 and 18-19 of the antisense strand.

[0278] In certain embodiments of formula (I), the base pair portion B is adenine. In certain embodiments of formula (I), the base pair portion B is guanine. In certain embodiments of formula (I), the base pair portion B is cytosine. In certain embodiments of formula (I), the base pair portion B is uracil.

[0279] In one embodiment of formula (I), W is O. In one embodiment of formula (I), W is CH2. In one embodiment of formula (I), W is CH.

[0280] In one embodiment of formula (I), X is OH. In one embodiment of formula (I), X is OCH3. In one embodiment of formula (I), X is halo.

[0281] In exemplary embodiments of formula (I), the modified oligonucleotide does not contain a 2'-fluoro substituent.

[0282] In one embodiment of formula (I), Y is O -In one embodiment of formula (I), Y is OH. In one embodiment of formula (I), Y is OR. In one embodiment of formula (I), Y is NH - In one embodiment of formula (I), Y is NH2. In one embodiment of formula (I), Y is S - In one embodiment of equation (I), Y is SH.

[0283] In one embodiment of formula (I), Z is O. In one embodiment of formula (I), Z is H2.

[0284] In one embodiment of formula (I), the linkage is inserted at positions 1-2 of the antisense chain. In another embodiment of formula (I), the linkage is inserted at positions 6-7 of the antisense chain. In yet another embodiment of formula (I), the linkage is inserted at positions 10-11 of the antisense chain. In yet another embodiment of formula (I), the linkage is inserted at positions 19-20 of the antisense chain. In one embodiment of formula (I), the linkage is inserted at positions 5-6 and 18-19 of the antisense chain.

[0285] Interconnections between modifying subunits are further described in WO2020 / 198509 and USSN63 / 000,328 (filed March 26, 2020), each of which is incorporated herein by reference.

[0286] 4) Conjugate function In other embodiments, the RNA silencing agent may be modified with one or more functional moieties. The functional moieties are molecules that confer one or more additional activities to the RNA silencing agent. In certain embodiments, the functional moieties enhance cellular uptake by target cells (e.g., nerve cells). Accordingly, the disclosure includes RNA silencing agents that are conjugated or unconjugated (e.g., at their 5' and / or 3' ends) to other moieties (e.g., non-nucleic acid moieties such as peptides) or organic compounds (e.g., dyes), etc. Conjugation can be achieved, for example, using the methods known in this technology, or the following methods: Lambert et al., Drug Deliv. Rev.:47(1),99-112(2001) (described on nucleic acids attached to polyalkylcyanoacrylate (PACA) nanoparticles); Fattal et al., J. Control Release 53(1-3):137-43(1998) (described on nucleic acids bound to nanoparticles); Schwab et al., Ann. Oncol. 5 Suppl. 4:55-8(1994) (described on nucleic acids linked to intercalating agents, hydrophobic groups, polycations, or PACA nanoparticles); and Godard et al., Eur. J. Biochem. 232(2):404-10(1995) (described on nucleic acids linked to nanoparticles).

[0287] In certain embodiments, the functional portion is a hydrophobic portion. In certain embodiments, the hydrophobic portion is selected from the group consisting of fatty acids, steroids, secosteroids, lipids, gangliosides and nucleoside analogs, endocannabinoids, and vitamins. In certain embodiments, the steroid is selected from the group consisting of cholesterol and lithocholic acid (LCA). In certain embodiments, the fatty acid is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosanic acid (DCA). In certain embodiments, the vitamin is selected from the group consisting of choline, vitamin A, vitamin E, their derivatives, and their metabolites. In certain embodiments, the vitamin is selected from the group consisting of retinoic acid and alpha-tocopherol succinate.

[0288] In certain embodiments, the RNA silencing agent of the disclosure is conjugated to a lipophilic moiety. In one embodiment, the lipophilic moiety is a ligand containing a cationic group. In another embodiment, the lipophilic moiety is attached to one or both strands of the siRNA. In an exemplary embodiment, the lipophilic moiety is attached to one end of the sense strand of the siRNA. In another exemplary embodiment, the lipophilic moiety is attached to the 3' end of the sense strand. In certain embodiments, the lipophilic moiety is selected from the group consisting of cholesterol, vitamin E, vitamin K, vitamin A, folic acid, and cationic dyes (e.g., Cy3). In an exemplary embodiment, the lipophilic moiety is cholesterol. Other lipophilic components include cholic acid, adamantane acetate, 1-pyrene butyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine.

[0289] In certain embodiments, the functional portion may include one or more ligands tethered to the RNA silencing agent to improve stability, hybridization thermodynamics with target nucleic acids, targeting to specific tissues or cell types, or cell permeability, for example, by endocytosis-dependent or independent mechanisms. The ligands and associated modifications may also enhance sequence specificity, thereby reducing off-site targeting. The tethering ligand may include one or more modified bases or sugars that can function as intercalators. These may also be located within internal regions, such as within the bulge of the RNA silencing agent / target double helix. The intercalators may be aromatic, e.g., polycyclic aromatic or heterocyclic aromatic compounds. Polycyclic intercalators may have stacking capabilities and may include systems having two, three, or four fused rings. The universal bases described herein may be included as ligands. In one embodiment, the ligand may include cleavage groups that contribute to the inhibition of the target gene by cleaving the target nucleic acid. The cleavage group may be, for example, bleomycin (e.g., bleomycin-A5, bleomycin-A2, or bleomycin-B2), pyrene, phenanthroline (e.g., O-phenanthroline), polyamine, tripeptide (e.g., lys-tyr-lys tripeptide), or a metal ion chelating group. Examples of metal ion chelating groups include Lu(III) or EU(III) macrocyclic complexes, Zn(II) 2,9-dimethylphenanthroline derivatives, Cu(II) terpyridine, or acridine, which can promote the selective cleavage of target RNA at the bulge region by free metal ions such as Lu(III). In some embodiments, the peptide ligand can be tethered to an RNA silencing agent to promote the cleavage of target RNA, for example, at the bulge region. For example, 1,8-dimethyl-1,3,6,8,10,13-hexaazacyclotetradecane (Cycram) can be conjugated into peptides (e.g., by amino acid derivatives) to facilitate target RNA cleavage.The tethering ligand can be an aminoglycoside ligand, which can impart improved hybridization properties or improved sequence specificity to the RNA silencing agent. Exemplary aminoglycosides include glycosylated polylysine, galactosylated polylysine, neomycin B, tobramycin, kanamycin A, and acridine conjugates of aminoglycosides, such as Neo-N-acridine, Neo-S-acridine, Neo-C-acridine, Tobra-N-acridine, and KanaA-N-acridine. The use of acridine analogs can enhance sequence specificity. For example, neomycin B has high affinity for RNA compared to DNA, but lower sequence specificity. The acridine analog neo-5-acridine has high affinity for HIV Rev-response elements (RREs). In some embodiments, guanidine analogs (guanidinoglycosides) of aminoglycoside ligands are tethered to the RNA silencing agent. Within guanidinoglycosides, the amine group on the amino acid is replaced with a guanidine group. The attachment of a guanidine analog can increase the cellular permeability of RNA silencing agents. The tethering ligand may be a polyarginine peptide, peptoid, or peptide mimetic that can increase the cellular uptake of oligonucleotide agents.

[0290] Exemplary ligands are coupled to ligand-conjugate carriers, either directly or indirectly via intervening tethering factors. In certain embodiments, the coupling is via covalent bonding. In certain embodiments, the ligand is attached to the carrier via intervening tethering factors. In certain embodiments, the ligand alters the distribution, targeting, or lifetime of the RNA silencing agent into which it is incorporated. In certain embodiments, the ligand provides, for example, higher affinity to selected targets, such as molecules, cells or cell types, compartments, such as cell or organ compartments, tissues, organs, or regions of the body, compared to species in which such ligands are absent.

[0291] Exemplary ligands can improve transport, hybridization, and specificity properties, and may also improve the nuclease resistance of polymer molecules and / or natural or modified ribonucleotides, including the resulting natural or modified RNA silencing agents or any combination of monomers described herein. Ligands can generally include, for example, therapeutic modifiers to increase uptake, e.g., diagnostic compounds or reporter groups to monitor distribution; crosslinkers; nuclease resistance-constituting moieties; and natural or aberrant nucleic acid bases. Common examples include lipophilic substances, lipids, steroids (e.g., ubaol, hecigenin, diosgenin), terpenes (e.g., triterpenes, e.g., sarsasapogenin, friederin, epifriederanol-deranolic acid-derived lithocholic acid), vitamins (e.g., folic acid, vitamin A, biotin, pyridoxal), carbohydrates, proteins, protein binders, integrin target molecules, polycations, peptides, polyamines, and peptide mimetic compounds. Ligands may include naturally occurring substances (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrates (e.g., dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, or hyaluronic acid); amino acids, or lipids. Ligands may also be recombinant or synthetic molecules, such as synthetic polymers, such as synthetic polyamino acids. Examples of polyamino acids include polylysine (PLL), poly-L-aspartic acid, poly-L-glutamic acid, styrene-maleic anhydride copolymer, poly(L-lactide-coglycolated) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacrylic acid), N-isopropylacrylamide polymer, or polyphosphatidine.Examples of polyamines include polyethyleneimine, polylysine (PLL), spermine, spermidine, polyamines, pseudopeptide-polyamines, peptide-mimicking polyamines, dendrimer polyamines, arginine, amidine, protamine, cationic lipids, cationic porphyrins, quaternary salts of polyamines, or alpha-helical peptides.

[0292] Ligands can also include target groups that bind to specific cell types, such as kidney cells, such as cell or tissue targeting agents, such as lectins, glycoproteins, lipids or proteins, such as antibodies. Target groups can also be thyroid-stimulating hormone, melanotropin, lectins, glycoproteins, surfactant protein A, mucin carbohydrates, polyvalent lactose, polyvalent galactose, N-acetylgalactosamine (GalNAc) or its derivatives, N-acetylglucosamine, polyvalent mannose, polyvalent fucose, glycosylated polyamino acids, polyvalent galactose, transferrin, bisphosphonates, polyglutamates, polyaspartates, lipids, cholesterol, steroids, bile acids, folates, vitamin B12, biotin, or RGD peptides or RGD peptide mimetic compounds. Other examples of ligands include dyes, intercalating agents (e.g., acridine and substituted acridines), crosslinking agents (e.g., psoralen, mitomycin C), porphyrins (TPPC4, texaphylline, saffrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine, phenanthroline, pyrene), lys-tyr-lys tripeptides, aminoglycosides, guanidium aminoglycosides, artificial endonucleases (e.g., EDTA), lipophilic molecules (e.g., cholesterol and its thio analogues), cholic acid, cholanic acid, lithocholic acid, adamantane acetate, 1-pyrenebutyric acid, dihydrotestosterone, glycerol (e.g., esters (e.g., mono, bis, or tris fatty acid esters, e.g., C) 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C18 , C 19 or C 20 fatty acids) and their ethers, for example, C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , or C 20 Alkyl groups (e.g., 1,3-bis-O(hexadecyl)glycerol, 1,3-bis-O(octadecyl)glycerol), geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, stearic acid (e.g., glyceryl distearate), oleic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine) and peptide conjugates (e.g., antexols). Napedia peptides, Tat peptides), alkylating agents, phosphates, amino acids, mercaptos, PEGs (e.g., PEG-40K), MPEG, [MPEG]2, polyamino acids, alkyl groups, substituted alkyl groups, radiolabeled markers, enzymes, haptens (e.g., biotin), transport / absorption enhancers (e.g., aspirin, naproxen, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu tetraazal macrorings) 3+ Examples include complexes, dinitrophenyl, HRP, or AP. In certain embodiments, the ligand is GalNAc or a derivative thereof.

[0293] In a particular embodiment, the above GalNAc is given by the following formula: [ka] It is represented as follows.

[0294] Ligands can be proteins such as glycoproteins, peptides such as molecules that have a specific affinity for the coligand, or antibodies such as antibodies that bind to specific cell types such as cancer cells, endothelial cells, or osteocytes. Examples of ligands include hormones and hormone receptors. They can also include non-peptide species, such as lipids, lectins, carbohydrates, vitamins, cofactors, polyvalent lactose, polyvalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine, polyvalent mannose, or polyvalent fucose. Examples of ligands include lipopolysaccharides, p38 MAP kinase activators, or NF-κB activators.

[0295] A ligand can be a substance, such as a drug, that can increase the uptake of RNA silencing agents into cells by, for example, disrupting the cytoskeleton of a cell, such as by disrupting the cell's microtubules, microfilaments, and / or intermediate filaments. Drugs may include, for example, taxone, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latranculine A, phalloidin, swinholide A, indanosine, or myoservin. Ligands can also increase the uptake of RNA silencing agents into cells by, for example, activating an inflammatory response. Exemplary ligands with such effects include tumor necrosis factor alpha (TNF-1), interleukin-1 beta, or gamma interferon. In one embodiment, the ligand is a lipid or lipid system molecule. Such a lipid or lipid system molecule can bind to a serum protein, such as human serum albumin (HSA). HSA-binding ligands enable the distribution of conjugates to target tissues, such as non-renal target tissues of the body. For example, the target tissue could be the liver, such as hepatic parenchymal cells. Other molecules that can bind to HSA can also be used as ligands. For example, naproxen or aspirin can be used. Lipids or lipid ligands can be used to (a) improve the degradation tolerance of the conjugate, (b) increase targeting or transport to target cells or cell membranes, and / or (c) modulate binding to serum proteins, such as HSA. Lipid ligands can be used to modulate, for example, control the binding of the conjugate to target tissues. For example, lipids or lipid ligands that bind more strongly to HSA are less likely to target the kidney and therefore less likely to be excreted from the body. Lipids or lipid ligands that do not bind less strongly to HSA can be used to target the conjugate to the kidney. In certain embodiments, the lipid ligand binds to HSA. The lipid ligand can bind to HSA with sufficient affinity so that the conjugate is distributed to tissues other than the kidney.However, the affinity is not intended to be strong enough to reverse HSA-ligand binding. In another embodiment, the lipid ligand binds weakly to HSA or not at all, so the conjugate is distributed to the kidney. Other parts that target kidney cells can also be used instead of, or in addition to, the lipid ligand.

[0296] In another embodiment, the ligand is a portion taken up by target cells, such as proliferating cells, such as a vitamin. These may be particularly useful in treating undesirable cell proliferation, such as disorders characterized by malignant or non-malignant forms, such as cancer cells. Representative vitamins include vitamins A, E, and K. Examples of other vitamins include B vitamins, such as folic acid, B12, riboflavin, biotin, pyridoxal, or other vitamins or nutrients taken up by cancer cells. Similarly included are HSA and low-density lipoprotein (LDL).

[0297] In another embodiment, the ligand is a cell permeabilizer, such as a helical cell permeator. In certain embodiments, the agent is amphiphilic. Exemplary agents are peptides such as tat or antennopedia. If the agent is a peptide, it may be modified, including the use of peptidyl mimicry, inverted isomers, non-peptide or pseudopeptide bonds, and D-amino acids. The helical agent may be an alpha-helical agent that may have a lipophilic phase and an oleophobic phase.

[0298] The ligand may be a peptide or a peptide mimetic. A peptide mimetic (also referred to herein as an oligopeptide mimetic) is a molecule that can be folded into a specific three-dimensional structure similar to that of a natural peptide. The attachment of peptides and peptide mimetics to oligonucleotide agents can affect the pharmacokinetic distribution of RNA silencing agents, for example, by improving cellular recognition and absorption. The peptide or peptide mimetic moiety may be about 5 to 50 amino acids long, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long. The peptide or peptide mimetic may be, for example, a cell-permeable peptide, a cationic peptide, an amphiphilic peptide, or a hydrophobic peptide (for example, mainly consisting of Tyr, Trp, or Phe). The peptide moiety may be a dendrimeric peptide, a restrictive peptide, or a cross-linked peptide. The peptide moiety may be an L-peptide or a D-peptide. Alternatively, the peptide moiety may contain a hydrophobic membrane translocation sequence (MTS). Peptides or peptide mimetic compounds can be encoded by random DNA sequences, such as peptides identified from phage presentation libraries or one-bead-one-compound (OBOC) combinatorial libraries (Lam et al., Nature 354:82-84, 1991). In exemplary embodiments, the peptide or peptide mimetic compound tethered to the RNA silencing agent via an incorporated monomer unit is a cell-targeted peptide, such as an arginine-glycine-aspartate (RGD) peptide or RGD mimic. Some peptide moieties can range in length from about 5 to about 40 amino acids. Peptide moieties can have structural modifications, such as improving stability or directing conformation. Any of the structural modifications described below may be used.

[0299] In certain embodiments, the functional portion is ligated to the 5' and / or 3' ends of the RNA silencing agent of the disclosure. In certain embodiments, the functional portion is ligated to the 5' and / or 3' ends of the antisense strand of the RNA silencing agent of the disclosure. In certain embodiments, the functional portion is ligated to the 5' and / or 3' ends of the sense strand of the RNA silencing agent of the disclosure. In certain embodiments, the functional portion is ligated to the 3' end of the sense strand of the RNA silencing agent of the disclosure.

[0300] In certain embodiments, the functional portion is linked to the RNA silencing agent by a linker. In certain embodiments, the functional portion is linked to the antisense strand and / or sense strand by a linker. In certain embodiments, the functional portion is linked to the 3' end of the sense strand by a linker. In certain embodiments, the linker is a cleavable linker. In certain embodiments, the cleavable linker includes a phosphodiester bond, a disulfide bond, an acid-unstable bond, or a photocleavable bond.

[0301] In certain embodiments, the cleavable linker comprises a dTdT dinucleotide having interphosphodiester nucleotide links.

[0302] In certain embodiments, the acid-unstable bond includes a β-thiopropionate bond or a carboxydimethylmaleic anhydride (CDM) bond.

[0303] In certain embodiments, the linker comprises a divalent or trivalent linker. In certain embodiments, the linker comprises an ethylene glycol chain, an alkyl chain, a peptide, RNA, DNA, a phosphodiester, a phosphorothioate, a phosphoramidate, an amide, a carbamate, or a combination thereof. In certain embodiments, the divalent or trivalent linker is [ka] (In the formula, n is 1, 2, 3, 4, or 5) Selected from.

[0304] In certain embodiments, the linker further comprises a phosphodiester or a phosphodiester derivative. In certain embodiments, the phosphodiester or phosphodiester derivative is [ka] (In the formula, X is O, S, or BH3) It is selected from the group consisting of the following.

[0305] Various functional components of this disclosure and means for conjugating them with RNA silencing agents are described in further detail in WO2017 / 030973A1 and WO2018 / 031933A2, which are incorporated herein by reference.

[0306] Methods for introducing nucleic acids, vectors, and host cells. The RNA silencing agents of this disclosure can be introduced directly into cells (e.g., nerve cells) (i.e., intracellularly), or they can be introduced from outside the cell into cavities, spaces, or the circulation of an organism, or they can be introduced orally, or by immersing cells or organisms in a solution containing nucleic acids. Blood vessels or extravascular circulation, the blood or lymphatic system, and cerebrospinal fluid are sites into which nucleic acids can be introduced.

[0307] The RNA silencing agents of this disclosure can be introduced using nucleic acid delivery methods known in the art, such as injection of a nucleic acid-containing solution, impact with nucleic acid-coated particles, immersion of cells or organisms in a nucleic acid solution, or electroporation of cell membranes in the presence of nucleic acids. Other methods known in the art for introducing nucleic acids into cells may also be used, such as lipid-mediated transport, chemical-mediated transport, and cationic liposome transfection, such as calcium phosphate. The nucleic acids may be introduced together with other components that perform one or more of the following activities: namely, enhancing nucleic acid uptake by cells, or increasing inhibition of target genes.

[0308] Physical methods for introducing nucleic acids include injection of an RNA-containing solution, impact with RNA-coated particles, immersion of cells or organisms in an RNA solution, or electroporation of the cell membrane in the presence of RNA. Viral constructs packaged in viral particles achieve both efficient introduction of the expression construct into cells and transcription of the RNA encoded by the expression construct. Other methods known in the art for introducing nucleic acids into cells, such as lipid-mediated transport, chemical-mediated transport, such as calcium phosphate, may also be used. Thus, the RNA may be introduced together with other components that perform one or more of the following activities: enhancing RNA uptake by cells, inhibiting single-strand annealing, stabilizing single strands, or otherwise increasing the inhibition of target genes.

[0309] RNA can be introduced directly into cells (i.e., into cells), or it can be introduced from outside cells into cavities, spaces, or the circulation of organisms, orally, or by immersing cells or organisms in a solution containing RNA. Blood vessels or extravascular circulation, the blood or lymphatic system, and cerebrospinal fluid are sites into which RNA can be introduced.

[0310] Cells possessing the target gene may originate from germline or somatic cells, totipotent or pluripotent, mitotic or non-mitotic, parenchymal tissue or epithelium, immortalized or transformed cells, etc. The above cells may be stem cells or differentiated cells. Examples of cell types to differentiate include adipocytes, fibroblasts, myocytes, cardiomyocytes, endothelial cells, neurons, glial cells, blood cells, megakaryocytes, lymphocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, leukocytes, granulocytes, keratinocytes, chondrocytes, osteoblasts, osteoclasts, hepatocytes, and cells of endocrine or exocrine glands.

[0311] Depending on the specific target gene and the dose of the delivered double-stranded RNA material, this process may partially or completely cause loss of function of the target gene. Typical results include a reduction or loss of gene expression in at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% or more of the target cells. Inhibition of gene expression refers to the absence (or observable reduction) of levels of protein and / or mRNA products from the target gene. Specificity refers to the ability to inhibit the target gene without apparent effect on other genes in the cell. The results of inhibition can be confirmed by examining the external characteristics of the cell or organism (as shown in the examples below) or by biochemical methods, such as RNA solution hybridization, nuclease protection, Northern hybridization, reverse transcription, gene expression monitoring by microarray, antibody binding, enzyme-linked immunosorbent assay (ELISA), Western blotting, radioimmunoassay (RIA), other immunoassays, and fluorescence-activated cell sorting (FACS).

[0312] For RNA-mediated inhibition in cell lines or organisms, gene expression can be conveniently assayed using reporters or drug resistance genes whose protein products are readily assayable. Examples of such reporter genes include acetohydroxy acid synthase (AHAS), alkaline phosphatase (AP), beta-galactosidase (LacZ), beta-glucolonidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), horseradish peroxidase (HRP), luciferase (Luc), nopalin synthase (NOS), octopine synthase (OCS), and their derivatives. Multiple select markers conferring resistance to ampicillin, bleomycin, chloramphenicol, gentamicin, hygromycin, kanamycin, lincomycin, methotrexate, phosphinothricin, puromycin, and tetracycline are available. Depending on the assay, quantification of gene expression levels can determine inhibition levels greater than 10%, 33%, 50%, 90%, 95%, or 99% compared to cells not treated by this disclosure. If the dose of injected material is small and the time elapsed since RNAi agent administration is long, a smaller percentage of cells (e.g., at least 10%, 20%, 50%, 75%, 90%, or 95% of target cells) may be inhibited. Quantification of intracellular gene expression may indicate similar levels of inhibition at the level of target mRNA accumulation or target protein translation. For example, the efficiency of inhibition may be determined by evaluating the amount of intracellular gene products. mRNA can be detected by a hybridization probe having a nucleotide sequence outside the region used for the inhibitory double-stranded RNA, or the translated polypeptide can be detected by an antibody produced against the polypeptide sequence in that region.

[0313] RNA may be introduced in an amount that allows for delivery of at least one copy per cell. Higher doses of the material (e.g., at least 5, 10, 100, 500, or 1000 copies / cell) may result in more effective inhibition, while lower doses may also be useful for specific applications.

[0314] In one exemplary embodiment, the efficacy of the RNAi agent of this disclosure (e.g., siRNA targeting the DGAT2 target sequence) is tested for its ability to specifically degrade target mRNA (e.g., production of DGAT2 mRNA and / or DGAT2 protein) in cells such as those in the liver or white adipose tissue. In certain embodiments, the cells in the liver or white adipose tissue include, but are not limited to, hepatocytes, Kupffer cells, hepatic stellate cells, hepatic endothelial cells, and adipocytes. Other readily transfectable cells, such as HeLa cells or COS cells, are also suitable for cell-based validation assays. The cells are transfected with human cDNA (e.g., human DGAT2 cDNA). The cells are co-transfected with a standard siRNA, modified siRNA, or a vector capable of producing siRNA from U-loop mRNA. The selective reduction of target mRNA (e.g., DGAT2 mRNA) and / or target protein (e.g., DGAT2 protein) is measured. The reduction of target mRNA or protein can be compared to the level of target mRNA or protein in the absence of the RNAi agent or in the presence of an RNAi agent that does not target DGAT2 mRNA. Exogenously introduced mRNA or protein (or endogenous mRNA or protein) can be assayed for comparison.

[0315] Recombinant adeno-associated viruses and vectors In certain exemplary embodiments, recombinant adeno-associated viruses (rAAVs) and their associated vectors can be used to deliver one or more siRNAs into cells, such as liver cells (e.g., hepatocytes or Kupffer cells). AAVs can infect many different cell types, although their infectivity varies based on serotype determined by the sequence of their capsid proteins. Several native AAV serotypes have been identified, with serotypes 1–9 being the most commonly used for recombinant AAVs. AAV-2 is the most well-studied and publicly available serotype. Examples of AAV-DJ systems include serotypes AAV-DJ and AAV-DJ / 8. These serotypes are created by DNA shuffling of multiple AAV serotypes and produce AAVs containing hybrid capsids with improved transduction efficiency into various cells and tissues in vitro (AAV-DJ) and in vivo (AAV-DJ / 8).

[0316] rAAV can be delivered to a subject in a composition according to any suitable method known in the art. rAAV can be suspended in a physiologically compatible carrier (i.e., a composition) and administered to a host animal, namely, a human, mouse, rat, cat, dog, sheep, rabbit, horse, cattle, goat, pig, guinea pig, hamster, chicken, turkey, or a non-human primate (e.g., macaque). In certain embodiments, the animal is a non-human host animal.

[0317] Delivery of one or more rAAVs to a mammalian subject can be, for example, by intramuscular injection or by administration into the bloodstream of the mammalian subject. Administration into the bloodstream may be by injection into a vein, artery, or any other vascular conduit. In certain embodiments, one or more rAAVs are administered into the bloodstream by isolated limb perfusion, a technique well known in surgical techniques, which essentially allows a person skilled in the art to isolate the limb from systemic circulation before administration of the rAAV virions. A variation of the isolated limb perfusion technique described in U.S. Patent No. 6,177,403 may also be used by a person skilled in the art to administer virions into the vascular structure of an isolated limb to potentially enhance transduction into muscle cells or tissues.

[0318] The compositions of this disclosure may include rAAV alone or in combination with one or more other viruses (e.g., a second rAAV encoding having one or more different transgenes). In certain embodiments, the compositions include one, two, three, four, five, six, seven, eight, nine, ten or more different rAAVs, each having one or more different transgenes.

[0319] The effective dose of rAAV is sufficient to target an animal for infection and target the desired tissue. In some embodiments, the effective dose of rAAV is sufficient to create a stable somatic cell transgenic animal model. The effective dose depends mainly on factors such as the species, age, body weight, health status, and target tissue, and therefore can vary from animal to animal and tissue to tissue. For example, the effective dose of one or more rAAVs is generally about 10 9 ~10 16 This ranges from approximately 1 ml to approximately 100 ml of solution containing the genome copy. In some cases, approximately 10 11 ~10 12 The dosage of the rAAV genome copy is appropriate. In certain embodiments, 10 12 rAAV genome copies are effective for targeting cardiac, hepatic, and pancreatic tissues. In some cases, stable transgenic animals can be produced by multiple doses of rAAV.

[0320] In some embodiments, the rAAV composition is particularly suitable when high rAAV concentrations are present (for example, about 10%). 13 The formulation is designed to reduce the aggregation of AAV particles in the composition (at a rate of genome copies / mL or higher). Methods for reducing rAAV aggregation are well known in the art and include, for example, the addition of surfactants, pH adjustment, and salt concentration adjustment (e.g., Wright et al. (2005) Molecular Therapy 12:171-178, which is incorporated herein by reference).

[0321] A recombinant AAV (rAAV) vector comprises at least a transgene and its regulatory sequence, as well as 5' and 3' AAV reverse terminal repeats (ITRs). This recombinant AAV vector is packaged in a capsid protein and delivered to selected target cells. In some embodiments, the transgene is a nucleic acid sequence heterogeneous to the vector sequence, which encodes a polypeptide, protein, functional RNA molecule (e.g., siRNA) or other gene product of interest. The nucleic acid coding sequence is operably ligated to the regulatory component in a manner that enables transcription, translation, and / or expression of the transgene in cells of the target tissue.

[0322] The AAV sequence of a vector typically contains cis-acting 5' and 3' reverse-terminal repeat (ITR) sequences (see, e.g., B.J. Carter, "Handbook of Parvoviruses," ed., P. Tijsser, CRC Press, pp. 155-168 (1990)). ITR sequences are usually about 145 base pairs long. In certain embodiments, substantially the entire sequence encoding the ITR is used intramolecularly, although some minor modifications to these sequences are permissible. The ability to modify these ITR sequences is within the scope of those skilled in the art (see, e.g., text, Sambrook et al., "Molecular Cloning. A Laboratory Manual," 2nd ed., Cold Spring Harbor Laboratory, New York (1989); and K. Fisher et al., J Virol., 70:520-532 (1996)). Examples of such molecules used in this disclosure are “cis-acting” plasmids containing a transgene, wherein the selected transgene sequence and associated regulatory elements are adjacent to 5' and 3' AAV ITR sequences. The AAV ITR sequences can be obtained from any known AAV, such as the mammalian AAV types further described herein.

[0323] VI. Treatment method In one embodiment, the disclosure provides both prophylactic and therapeutic methods for subjects at risk of (or prone to) developing diseases associated with lipid metabolism dysregulation, by inhibiting DGAT2, which catalyzes triglyceride synthesis. Diseases associated with lipid metabolism dysregulation include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), dyslipidemia, lipodystrophy syndromes, and metabolic syndromes (MetS), the latter of which are associated with an increased risk of developing atherosclerotic cardiovascular disease (CVD), stroke, and type 2 diabetes. Generally, treatment results in a decrease in serum levels of at least one other liver enzyme besides DGAT2 (e.g., stearoyl-CoA desaturase-1 (SCD1) or fatty acid synthase (FASN)) and / or a reduction in hepatic lipid accumulation.

[0324] As used herein, “treatment” or “to treat” is defined as the application or administration of a therapeutic agent (e.g., an RNA agent or vector or a transgene encoding it) to a patient, or the application or administration of a therapeutic agent to tissue or cell lines isolated from a patient, the patient having the disease or disorder, the symptoms of the disease or disorder or a predisposition to the disease or disorder, and the treatment being performed to treat, cure, reduce, alleviate, modify, repair, restore, improve or influence the disease or disorder, the symptoms of the disease or disorder or a predisposition to the disease or disorder.

[0325] In one embodiment, the Disclosure provides a method for preventing the aforementioned disease or disorder in a subject by administering a therapeutic agent (e.g., an RNAi agent or vector or a transgene encoding the same) to the subject. Subjects at risk of the disease can be identified, for example, by one or a combination of the diagnostic assays or prognostic assays described herein. Administration of the prophylactic agent can be performed before the appearance of symptoms characteristic of the disease or disorder, thereby preventing the disease or disorder or slowing its progression.

[0326] Another aspect of this disclosure relates to methods for therapeutically treating a subject, i.e., methods for altering the onset of symptoms of a disease or disorder. In exemplary embodiments, the modulatory methods of this disclosure involve contacting hepatocytes expressing DGAT2 with a therapeutic agent (e.g., an RNAi agent, a vector, or a transgene encoding them) that is specific to a target sequence in the gene (e.g., the DGAT2 target sequence in Table 1), thereby achieving sequence-specific gene interference. These methods can be performed in vitro (e.g., by culturing cells with the agent) or in vivo (e.g., by administering the agent to the subject).

[0327] VII. Pharmaceutical Compositions and Methods of Administration This disclosure relates to the use of the above-mentioned agents for prophylactic and / or therapeutic treatment as described below. Accordingly, the modifiers of this disclosure (e.g., RNAi agents) can be incorporated into pharmaceutical compositions suitable for administration. Such compositions generally comprise nucleic acid molecules or modifier compounds and pharmaceutically acceptable carriers. In this specification, the term “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antimicrobial and antifungal agents, isotonic and absorption retarders, etc., that are suitable for drug administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agent is incompatible with the active compound, their use in compositions is contemplated. Complementary active compounds can also be incorporated into compositions.

[0328] The pharmaceutical compositions of this disclosure are formulated to be compatible with their intended route of administration. Examples of routes of administration include parenteral administration, such as intravenous administration, and subcutaneous administration.

[0329] The nucleic acid molecules of this disclosure can be inserted into expression constructs, for example, viral vectors, retroviral vectors, expression cassettes, or plasmid viral vectors, using methods known in the art, including, but not limited to, those described above in Xia et al., (2002). The expression constructs can be delivered to a target, for example, by inhalation, oral administration, intravenous injection, topical administration (see U.S. Patent No. 5,328,470), or stereotactic injection (see, for example, Chen et al. (1994), Proc. Natl. Acad. Sci. USA, 91, 3054-3057). The pharmaceutically appropriate preparation of the delivery vector may include the vector in an acceptable diluent, or it may include a sustained-release matrix into which the delivery vehicle is embedded. Alternatively, if the complete delivery vector can be produced intact from recombinant cells, such as a retroviral vector, the pharmaceutically appropriate preparation may include one or more cells that produce the gene delivery system.

[0330] The nucleic acid molecules of this disclosure may also include small hairpin RNAs (shRNAs) and expression constructs engineered to express shRNAs. ShRNA transcription is thought to be initiated by the polymerase III (pol III) promoter and terminated at position 2 of the 4-5-thymine transcription termination site. Upon expression, shRNAs are thought to fold into a stem-loop structure with a 3' UU overhang. Subsequently, the ends of these shRNAs are processed, converting them into approximately 21-nucleotide siRNA-like molecules. Brummelkamp et al. (2002), Science, 296, 550-553; Lee et al. (2002). See above; Miyagishi and Taira (2002), Nature Biotechnol., 20, 497-500; Paddison et al. (2002), See above; Paul (2002), See above; Sui (2002), See above; Yu et al. (2002), See above.

[0331] The expression constructs described above may be any construct suitable for use in a suitable expression system, including, but not limited to, retroviral vectors, linear expression cassettes, plasmids, and viruses or virus-derived vectors known in the art. Such expression constructs may include one or more inducible promoters, RNA Pol III promoter systems, e.g., the U6 snRNA promoter or the H1 RNA polymerase III promoter, or other promoters known in the art. The constructs may include one or both strands of the siRNA. Expression constructs expressing both strands may also include a loop structure linking both strands, or each strand may be transcribed separately from separate promoters within the same construct. Each strand may also be transcribed from another expression construct (Tuschl (2002), above).

[0332] For example, a composition may include one or more compounds of the species of the Disclosure and a pharmaceutically acceptable carrier. The pharmaceutical compositions of the Disclosure may be delivered by intravenous or subcutaneous injection.

[0333] It will be readily apparent to those skilled in the art that other suitable modifications and adaptations of the methods described herein can be made using suitable equivalents without departing from the scope of the embodiments disclosed herein. While specific embodiments have been described in detail so far, the same will be more clearly understood by referring to the following examples, which are included for illustrative purposes only and are not intended to limit the scope of the embodiments disclosed herein. [Examples]

[0334] Example 1: Identification of DGAT2 target sequences in vitro The DGAT2 gene described above was used as the target for mRNA knockdown. A group of cholesterol-conjugate siRNA double-stranded cells possessing homology to both human and mouse DGAT2 and targeting several different sequences of DGAT2 mRNA were developed and screened in vitro in human HepG2 and mouse FL83B hepatocyte lines, compared to untreated control cells (Figure 1A). The siRNA double-stranded cells were designed to target the open reading frame (ORF) and the 3' untranslated region (3'UTR) (Table 1 and Figure 1B). Each siRNA double-stranded cell was tested at a concentration of 1.5 μM, and the mRNA was evaluated at 72 hours using a QuantiGene gene expression assay (ThermoFisher, Waltham, MA). Figure 1C shows the results of screening for mouse DGAT2 mRNA, evaluating seven DGAT2 siRNA double-stranded cells in FL83B mouse cells. Three sites were identified that elicited potent and effective silencing of DGAT2 mRNA compared to the untreated control. The three identified siRNA double strands, oligonucleotide identification numbers 1093, 1473, and 1476, were further screened against human DGAT2 mRNA in the HepG2 cell line, and two of the three siRNA double strands, identification numbers 1473 and 1476, were identified as the most potent (Figure 1D). Dose-response curves were constructed in the HepG2 cell line for the identified lead siRNA double strands 1473 and 1476 to confirm their efficacy (Figure 1E).

[0335] Table 1 lists the 120-nucleotide DGAT2 target region, as well as the sense and antisense strands of the siRNA double-stranded molecules screened in Figures 1 and 2. The antisense strand contains 5'-uracil to enhance the loading in RISC.

[0336] Example 2: Verification of in vivo DGAT2 silencing using cholesterol-conjugated siRNA. To test whether the lead siRNA double strands identified by the in vitro screening described above silence DGAT2 in vivo, 8-week-old wild-type C57BL6 / J mice fed solid feed were subcutaneously injected with either 10 mg / kg of cholesterol-conjugate untargeted control (Chol-NTC) or a DGAT2-targeting cholesterol-conjugate 1473 compound (Chol-1473). Mice were sacrificed 10 days after injection. Measurement of mRNA expression and analysis of liver samples for protein knockdown levels showed that the modified siRNA double strands potently and effectively silenced mouse DGAT2 mRNA expression in vivo (Figures 2A and 2B).

[0337] Example 3: Verification of in vivo DGAT2 silencing using N-acetylgalactosamine (GalNAc) conjugate 1473 tool compound. To test whether the GalNAc conjugate compound 1473 can potently silence DGAT2 in vivo, 8-week-old C57BL6 / J wild-type mice fed solid feed were subcutaneously injected once with different doses of GalNAc-1473 (10, 3, 1 mg / kg) or a non-targeted control compound (10 mg / kg) (Figure 3A), and sacrificed 4, 8, or 12 weeks after injection. Liver samples were processed for mRNA expression measurement. DGAT2 silencing in the liver was still sufficient 12 weeks after a single subcutaneous injection of GalNAc-1473 (Figure 3B), and mRNA analysis showed that DGAT2 silencing altered the expression of genes involved in de novo lipid biosynthesis (Figure 3C).

[0338] Example 4: Silencing of DGAT2 by GalNAc-1473 in humanized NSG mice with transplanted human hepatocytes. To test the efficacy of GalNAc-1473 in simultaneously silencing both mouse and human DGAT2 transcripts, a human hepatocyte-transplanted NSG mouse model was created (Figure 4A). These mice were fed solid diet for 5 weeks after transplantation, then administered a single subcutaneous injection of 10 mg / kg of GalNAc-1473 or a non-targeted control compound. They were sacrificed one week after injection, and liver samples were processed for mRNA expression measurement. RNA analysis of DGAT2 expression showed significant silencing in both homologies (Figures 4B and 4C).

[0339] Example 5: In vivo efficacy study of DGAT2 silencing with GalNAc-1473 in a NAFLD / NASH mouse model. To test the efficacy of GalNAc-1473 in silencing DGAT2 in an animal model of NAFLD / NASH, 10-week-old genetically obese (ob / ob) mice were subcutaneously injected with either a 10 mg / kg dose of GalNac conjugate untargeted control (GalNac-NTC) or GalNac-1473. On the day of injection, the mice were then switched to a high-fat, high-cholesterol GAN ​​diet to induce a metabolic NASH phenotype. Blood samples were collected one week after injection, and the mice were sacrificed three weeks after injection. mRNA and protein analysis of liver tissue showed significant knockdown of DGAT2 in mice injected with GalNac-1473 (Figure 5A). Measurements of liver weight and liver-to-body weight ratio showed a significant reduction in liver weight due to DGAT2 silencing (Figures 5B and 5C). Measurement of alanine aminotransferase (ALT), a serum marker for liver damage, showed no significant difference between treated mice and control mice (Figure 5D).

[0340] For histological analysis, mouse liver tissue samples were fixed in 4% formalin at room temperature for 24 hours, dehydrated with graded ethanol, and embedded in paraffin. Tissue sections (5 μm thick) were deparaffinized with xylene and stained with hematoxylin and eosin. H&E staining showed reduced hepatic fat accumulation in NASH mice treated with GalNAc-1473 compared to GalNAc-NTC mice (Figure 5E). Analysis of hepatic triglyceride (TG) concentrations showed a significant decrease in total hepatic triglycerides after DGAT2 silencing, as shown in Figure 5F. Diglyceride (DAG) concentrations and aliphatic acyl chain content in triglycerides (all measured by mass spectrometry) also decreased, as shown in Figure 5F.

[0341] Phospholipid levels were also evaluated in ob / ob mice suffering from NASH. As shown in Figures 7A-7C, phosphatidylcholine (Figure 7A), phosphatidylethanolamine (Figure 7B), and phosphatidylinositol (Figure 7C) levels were all elevated in mice injected with GalNAc-1473 compared to GalNAc-NTC mice, which was consistent with DGAT2 knockdown.

[0342] DGAT2 mRNA levels were also measured in 8-week-old male C57BL6 mice injected with GalNAc-NTC or GalNAc-1473. DGAT2 silencing in the kidneys, spleen, inguinal fat, epididymal fat, and liver was examined by qPCR after injection of 10 mg / kg of siRNA into the mice. As shown in Figure 8, DGAT2 was preferentially silenced in the liver.

[0343] Example 6: Effect of DGAT2 silencing on the transcription of genes involved in de novo lipid biosynthesis in mice with NASH. Gene expression analysis of liver tissue from NAFLD / NASH mice treated with GalNac-NTC or GalNac-1473 and fed a high-fat, high-cholesterol GAN ​​diet showed that DGAT2 knockdown significantly altered the expression of genes involved in hepatic de novo lipid biosynthesis (Figure 6A). Changes were also observed in post-translational modifications and protein expression levels of transcription factors involved in de novo lipid biosynthesis gene expression (Figures 6B and 6C). [Table 1-1] [Table 1-2] [Table 2] [Table 3] [Table 4]

[0344] support All references (including references to documents, patents, patent applications, and websites) that may be cited throughout this application are expressly incorporated in their entirety for any purpose, just as references are expressed herein. Unless otherwise expressly stated, this disclosure utilizes conventional methods of immunology, molecular biology, and cell biology that are well known in the art.

[0345] This disclosure also draws upon, as a whole, techniques that are well known in the fields of molecular biology and drug delivery. These techniques include, but are not limited to, those described in the following publications. Atwell et al. J. Mol. Biol. 1997, 270: 26-35; Ausubel et al. (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &Sons, NY (1993); Ausubel,F.M.et al.eds.,SHORT PROTOCOLS IN MOLECULAR BIOLOGY(4th Ed.1999)John Wiley & Sons,NY.(ISBN 0-471-32938-X); CONTROLLED DRUG BIOAVAILABILITY,DRUG PRODUCT DESIGN AND PERFORMANCE,Smolen and Ball(eds.),Wiley,New York(1984); Giege,R.and Ducruix,A.Barrett,CRYSTALLIZATION OF NUCLEIC ACIDS AND PROTEINS,a Practical Approach,2nd ea.,pp.20 1-16,Oxford University Press,New York,New York,(1999); Goodson,in MEDICAL APPLICATIONS OF CONTROLLED RELEASE,vol.2,pp.115-138(1984); Hammerling,et al.,in: MONOCLONAL ANTIBODIES AND T-CELL HYBRIDOMAS 563-681(Elsevier,N.Y.,1981; Harlow et al.,ANTIBODIES: A LABORATORY MANUAL,(Cold Spring Harbor Laboratory Press,2nd ed.1988); Kabat et al.,SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST(National Institutes of Health,Bethesda,Md.(1987)and(1991); Kabat,E.A.,et al.(1991)SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST,Fifth Edition,U.S.Department of Health and Human Services,NIH Publication No.91-3242; Kontermann and Dubel eds.,ANTIBODY ENGINEERING(2001)Springer-Verlag.New York.790 pp.(ISBN 3-540-41354-5); Kriegler,Gene Transfer and Expression,A Laboratory Manual,Stockton Press,NY(1990); Lu and Weiner eds.,CLONING AND EXPRESSION VECTORS FOR GENE FUNCTION ANALYSIS(2001)BioTechniques Press.Westborough,MA.298 pp.(ISBN 1-881299-21-X); MEDICAL APPLICATIONS OF CONTROLLED RELEASE,Langer and Wise(eds.),CRC Pres.,Boca Raton,Fla.(1974); Old,R.W.& S.B.Primrose,PRINCIPLES OF GENE MANIPULATION: AN INTRODUCTION TO GENETIC ENGINEERING(3d Ed.1985)Blackwell Scientific Publications,Boston.Studies in Microbiology;V.2:409 pp.(ISBN 0-632-01318-4); Sambrook, J. et al. eds., MOLECULAR CLONING: A LABORATORY MANUAL (2d Ed.1989) Cold Spring Harbor Laboratory Press, NY. Vols. 1-3. (ISBN 0-87969-309-6); SUSTAINED AND CONTROLLED RELEASE DRUG DELIVERY SYSTEMS, JR Robinson, ed., Marcel Dekker, Inc., New York, 1978; Winnacker, ELFROM GENES TO CLONES: INTRODUCTION TO GENE TECHNOLOGY (1987) VCH Publishers, NY (translated by Horst Ibelgaufts). 634 pp. (ISBN 0-89573-614-4).

[0346] Equal parts This disclosure can be embodied in other specific forms without departing from its spirit or essential features. Therefore, the embodiments described above should be considered illustrative in all respects and not limiting. Accordingly, the scope of this disclosure is indicated not by the foregoing description but by the appended claims, and all modifications that fall within the meaning and equivalents of the claims are intended to be incorporated herein.

Claims

1. A double-stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, The molecule, wherein the antisense strand comprises a sequence substantially complementary to a diacylglycerol O-acyltransferase 2 (DGAT2) nucleic acid sequence of any one of SEQ ID NOs: 1-5.

2. the antisense strand comprises a sequence substantially complementary to a DGAT2 nucleic acid sequence of any one of SEQ ID NOs: 6-10; and optionally, the dsRNA comprises complementarity to at least 10, 11, 12, or 13 consecutive nucleotides of the DGAT2 nucleic acid sequence of any one of SEQ ID NOs: 1-10, and / or no more than 3 mismatches with the DGAT2 nucleic acid sequence of any one of SEQ ID NOs: 1-10, or perfect complementarity to the DGAT2 nucleic acid sequence of any one of SEQ ID NOs: 1-10; and / or the antisense strand comprises about 15 to 25 nucleotides in length, or 20, 21 or 22 nucleotides in length; and / or the sense strand comprises about 15 to 25 nucleotides in length, or 15, 16, 18, 20 or 21 nucleotides in length; and / or the dsRNA comprises a double-stranded region of 15 to 20 base pairs, or 15, 16, 18, 20 or 21 base pairs; and / or The dsRNA comprises blunt ends or at least one single-stranded nucleotide overhang, and optionally the dsRNA comprises a single-stranded nucleotide overhang of about 2 to 5 nucleotides; or the dsRNA comprises a single-stranded nucleotide overhang of 2 nucleotides; or the dsRNA comprises a single-stranded nucleotide overhang of 5 nucleotides; and / or the dsRNA comprises naturally occurring nucleotides, or The dsRNA comprises at least one modified nucleotide, and optionally the modified nucleotide comprises a 2'-O-methyl modified nucleotide, a 2'-deoxy-2'-fluoro modified nucleotide, a 2'-deoxy modified nucleotide, a locked nucleotide, an abasic nucleotide, a 2'-amino modified nucleotide, a 2'-alkyl modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base containing nucleotide, or a mixture thereof; and / or the dsRNA comprises at least one modified internucleotide linkage, and optionally the modified internucleotide linkage comprises a phosphorothioate internucleotide linkage; and / or the dsRNA comprises 4 to 16 phosphorothioate internucleotide linkages or 4 to 13 phosphorothioate internucleotide linkages, and optionally the dsRNA comprises 8 or 13 phosphorothioate internucleotide linkages, or optionally The dsRNA has Formula I: 【Chemistry 1】 (In the formula, B is a base pair moiety; W is O, OCH 2 , O.C.H., C.H. 2 and CH; X is halo, hydroxy, and C 1-6 alkoxy; Y is O - , OH, OR, NH - , N.H. 2 , S - and SH, Z is O and CH 2 selected from the group consisting of: R is a protecting group; 【Chemistry 2】 is a bond which is optionally a double bond) and / or The dsRNA comprises at least 80% chemically modified nucleotides, and optionally The dsRNA is fully chemically modified, or the dsRNA contains at least 70% 2'-O-methyl nucleotide modifications; or the antisense strand comprises at least 70% 2'-O-methyl nucleotide modifications, and optionally the antisense strand comprises 70% to 90% 2'-O-methyl nucleotide modifications; or the sense strand comprises at least 65% 2'-O-methyl nucleotide modifications, and optionally the sense strand comprises 100% 2'-O-methyl nucleotide modifications; and / or the sense strand comprises one or more nucleotide mismatches between the antisense strand and the sense strand, and optionally the one or more nucleotide mismatches are at positions 2, 6, and 12 from the 5' end of the sense strand; or the nucleotide mismatches are at positions 2, 6, and 12 from the 5' end of the sense strand; and / or the antisense strand comprises a 5' phosphate, a 5'-alkyl phosphonate, a 5' alkylene phosphonate, or a 5' alkenyl phosphonate, and optionally The dsRNA molecule of claim 1, wherein the antisense strand comprises a 5' vinyl phosphonate.

3. The dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end; A: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, 14, and 16 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains at least 70% 2'-O-methyl modifications; (7) the nucleotides 1 to 2 from the 5' end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage; or B: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 4, 5, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains 100% 2'-O-methyl modifications; (7) the nucleotides 1 to 2 from the 5' end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage; or C: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 4, 5, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains 100% 2'-O-methyl modifications; (7) the nucleotides 1 to 2 from the 5' end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage; or D: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 80% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 4, and 14 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains at least 80% 2'-O-methyl modifications; (7) the nucleotides 1 to 2 from the 5' end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage; or E: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, 14, 16, and 20 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains at least 70% 2'-O-methyl modifications; (7) the nucleotides at positions 7 and 9 to 11 from the 3' end of the sense strand are not 2'-methoxy-ribonucleotides; (8) the nucleotides 1 to 2 from the 5' end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage; or F: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains at least 70% 2'-O-methyl modifications; (7) the nucleotides at positions 7, 10, and 11 from the 3' end of the sense strand are not 2'-methoxy-ribonucleotides; (8) The 1st to 2nd nucleotides from the 5'-end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage. The dsRNA molecule of claim 1.

4. the nucleotide at position 20 from the 5' end of the antisense strand is not a 2'-methoxy-ribonucleotide; and / or a functional moiety is linked to the 5'-end and / or the 3'-end of the antisense strand; and / or a functional moiety is linked to the 5'-end and / or the 3'-end of the sense strand; and / or The dsRNA molecule of claim 1 or 3, wherein a functional moiety is linked to the 3' end of the sense strand.

5. the functional moiety comprises an N-acetylgalactosamine (GalNAc) moiety; and / or The functional moiety comprises a hydrophobic moiety, and optionally the hydrophobic moiety is selected from the group consisting of fatty acids, steroids, secosteroids, lipids, gangliosides, nucleoside analogs, endocannabinoids, vitamins, and mixtures thereof; and optionally the steroid is selected from the group consisting of cholesterol and lithocholic acid (LCA); or 5. The dsRNA molecule of claim 4, wherein the fatty acid is selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosanoic acid (DCA).

6. the functional moiety is linked to the antisense strand and / or the sense strand by a linker, and optionally the linker is a cleavable linker, optionally the cleavable linker comprises a dTdT dinucleotide having a phosphodiester bond, a disulfide bond, an acid labile bond, a photocleavable bond, or a phosphodiester internucleotide linkage, optionally the acid labile bond comprises a β-thiopropionate bond or a carboxydimethylmaleic anhydride (CDM) bond; and / or The linker comprises a bivalent or trivalent linker, optionally the bivalent or trivalent linker comprises: 【Chemistry 3】 wherein n is 1, 2, 3, 4, or 5. and / or the linker comprises an ethylene glycol chain, an alkyl chain, a peptide, RNA, DNA, a phosphodiester, a phosphorothioate, a phosphoramidate, an amide, a carbamate, or a combination thereof; and / or When the linker is a trivalent linker, the linker further links a phosphodiester or phosphodiester derivative, and optionally The phosphodiester or phosphodiester derivative is 【Chemistry 4】 (wherein X is O, S, or BH 3 (It is) The dsRNA molecule of claim 5, selected from the group consisting of:

7. nucleotides 1 and 2 from the 3' end of the sense strand and 1 and 2 from the 5' end of the antisense strand are linked to adjacent ribonucleotides via phosphorothioate bonds, and optionally the dsRNA inhibits expression of the DGAT2 gene by at least about 50%; or The dsRNA inhibits expression of one or more of the SREBP1c, FASN, SCD1, and ACC1 genes by at least about 50%; The dsRNA molecule according to any one of claims 1 to 6.

8. A pharmaceutical composition for inhibiting the expression of the diacylglycerol O-acyltransferase 2 (DGAT2) gene in an organism, comprising a dsRNA molecule according to any one of claims 1 to 7 and a pharma- ceutically acceptable carrier, optionally comprising: The pharmaceutical composition, wherein the dsRNA inhibits expression of the DGAT2 gene by at least about 50% or by at least 80%.

9. An agent for inhibiting expression of the DGAT2 gene in a cell, comprising the dsRNA molecule according to claim 1.

10. A pharmaceutical for treating or managing a disease associated with DGAT2 in a patient in need of such treatment comprising a dsRNA molecule according to any one of claims 1 to 7, optionally comprising: The medicament, wherein the disease is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), lipodystrophy, partial lipodystrophy, metabolic syndrome, cardiovascular disease, or a combination thereof.

11. A vector comprising a regulatory sequence operably linked to a nucleotide sequence encoding a dsRNA molecule substantially complementary to a DGAT2 nucleic acid sequence of SEQ ID NO: 1-10, optionally comprising: the dsRNA molecule inhibits expression of the DGAT2 gene by at least 30%, or A vector, wherein the dsRNA molecule inhibits expression of the DGAT2 gene by at least about 80%.

12. A recombinant adeno-associated virus (rAAV) comprising the vector of claim 11 and an AAV capsid.

13. A pharmaceutical for treating or managing a disease associated with DGAT2 in a patient in need of such treatment, comprising a double-stranded RNA (dsRNA) molecule, the dsRNA molecule comprising a sense strand and an antisense strand, the antisense strand comprises a sequence substantially complementary to a diacylglycerol O-acyltransferase 2 (DGAT2) nucleic acid sequence; and wherein the dsRNA molecule inhibits DGAT2 gene expression by at least about 50% for 4 weeks after administration; and optionally, the dsRNA molecule inhibits DGAT2 gene expression by at least about 50% for 8 weeks after administration; or the dsRNA molecule inhibits DGAT2 gene expression by at least about 50% for 12 weeks after administration; and / or the dsRNA molecule inhibits DGAT2 gene expression by at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, or at least about 90%; and / or the dsRNA molecule inhibits DGAT2 gene expression by about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or about 90%; and / or the dsRNA is administered at a dose of about 0.1 mg / kg to about 100 mg / kg, or at a dose of about 0.1 mg / kg, about 0.3 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 3 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, or about 30 mg / kg; and / or the antisense strand comprises a sequence substantially complementary to a DGAT2 nucleic acid sequence of SEQ ID NO: 1-10; and / or the antisense strand comprises complementarity to at least 10, 11, 12, or 13 consecutive nucleotides of a DGAT2 nucleic acid sequence of any one of SEQ ID NOs: 1-10; or the antisense strand contains no more than three mismatches with a DGAT2 nucleic acid sequence of any one of SEQ ID NOs: 1-10; or the antisense strand comprises perfect complementarity to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1-10; and / or the antisense strand comprises about 15 to 25 nucleotides in length; and / or the sense strand comprises about 15 to 25 nucleotides in length; optionally, the antisense strand is 20, 21 or 22 nucleotides in length; and / or the sense strand is 15, 16, 18 or 20 nucleotides in length; and / or the dsRNA molecule comprises a double-stranded region of 15 to 20 base pairs, and optionally the dsRNA molecule comprises a double-stranded region of 15, 16, 18 or 20 base pairs; and / or the dsRNA comprises blunt ends or the dsRNA comprises at least one single-stranded nucleotide overhang, and optionally the dsRNA comprises a single-stranded nucleotide overhang of about 2 to 5 nucleotides; or the dsRNA comprises a single-stranded nucleotide overhang of 2 nucleotides; or the dsRNA comprises a single-stranded nucleotide overhang of 5 nucleotides; and / or the dsRNA comprises at least one modified nucleotide, and optionally the modified nucleotide comprises a 2'-O-methyl modified nucleotide, a 2'-deoxy-2'-fluoro modified nucleotide, a 2'-deoxy modified nucleotide, a locked nucleotide, an abasic nucleotide, a 2'-amino modified nucleotide, a 2'-alkyl modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base containing nucleotide, or a mixture thereof; and / or the dsRNA comprises at least one modified internucleotide linkage, and optionally the modified internucleotide linkage comprises a phosphorothioate internucleotide linkage; optionally, the dsRNA contains 4 to 16 phosphorothioate internucleotide linkages; or the dsRNA comprises 4 to 13 phosphorothioate internucleotide linkages; optionally, the dsRNA comprises at least 80% chemically modified nucleotides; or the dsRNA is fully chemically modified, or the dsRNA comprises at least 70% 2'-O-methyl nucleotide modifications, and optionally the antisense strand comprises at least 70% 2'-O-methyl nucleotide modifications; or the antisense strand comprises 70%-90% 2'-O-methyl nucleotide modifications, and optionally the sense strand contains at least 65% 2'-O-methyl nucleotide modifications; or the sense strand comprises 100% 2'-O-methyl nucleotide modifications; and / or the antisense strand comprises a 5' phosphate, a 5'-alkyl phosphonate, a 5' alkylene phosphonate, or a 5' alkenyl phosphonate, and optionally A pharmaceutical agent wherein the antisense strand comprises a 5' vinyl phosphonate.

14. the dsRNA comprises an antisense strand and a sense strand, each strand having a 5' end and a 3' end; A: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, 14, and 16 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains at least 70% 2'-O-methyl modifications; (7) the nucleotides 1 to 2 from the 5' end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage; or B: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 4, 5, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains 100% 2'-O-methyl modifications; (7) the nucleotides 1 to 2 from the 5' end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage; or C: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 4, 5, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains 100% 2'-O-methyl modifications; (7) the nucleotides 1 to 2 from the 5' end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage; or D: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 80% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 4, and 14 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains at least 80% 2'-O-methyl modifications; (7) the nucleotides 1 to 2 from the 5' end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage; or E: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, 14, 16, and 20 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains at least 70% 2'-O-methyl modifications; (7) the nucleotides at positions 7 and 9 to 11 from the 3' end of the sense strand are not 2'-methoxy-ribonucleotides; (8) the nucleotides 1 to 2 from the 5' end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage; or F: (1) the antisense strand comprises a sequence substantially complementary to any one of the DGAT2 nucleic acid sequences of SEQ ID NOs: 1 to 10; (2) the antisense strand contains at least 70% 2'-O-methyl modifications; (3) the nucleotides at positions 2, 6, and 14 from the 5' end of the antisense strand are not 2'-methoxy-ribonucleotides; (4) nucleotides 1-2 through 1-7 from the 3' end of the antisense strand are linked to each other via phosphorothioate internucleotide linkages; (5) a portion of the antisense strand is complementary to a portion of the sense strand; (6) the sense strand contains at least 70% 2'-O-methyl modifications; (7) the nucleotides at positions 7, 10, and 11 from the 3' end of the sense strand are not 2'-methoxy-ribonucleotides; (8) The 1st to 2nd nucleotides from the 5'-end of the sense strand are linked to each other via a phosphorothioate internucleotide linkage. The pharmaceutical composition according to claim 13.

15. The antisense strand of claim 1, wherein the nucleotide at position 20 from the 5' end is not a 2'-methoxy-ribonucleotide; or a functional moiety is linked to the 5'-end and / or the 3'-end of the antisense strand; or a functional moiety is linked to the 5'-end and / or the 3'-end of the sense strand; or a functional moiety is linked to the 3' end of the sense strand; and optionally, the functional moiety comprises an N-acetylgalactosamine (GalNAc) moiety or a hydrophobic moiety, and optionally the hydrophobic moiety is selected from the group consisting of fatty acids, steroids, secosteroids, lipids, gangliosides, nucleoside analogs, endocannabinoids, vitamins, and mixtures thereof; and optionally The method of claim 14, wherein the steroid is selected from the group consisting of cholesterol and lithocholic acid (LCA).